

Tocilizumab P-S

1068.

[\[Interleukin 6 in the physiopathology of rheumatoid arthritis\].](#)

Pablos Álvarez JL.

Reumatol Clin. 2009 Feb;5(1):34-9. doi: 10.1016/S1699-258X(09)70203-7. Epub 2009 Feb 28.

Spanish.

PMID:

21794573 Espanjaa. **ei oteta**

[PubMed]

[Free Article](#)

[Related citations](#)

Efficacy of **tocilizumab** monotherapy after response to combined **tocilizumab** and methotrexate in patients with rheumatoid **arthritis**: the randomised JUST-ACT study.

Pablos JL, Navarro F, Blanco FJ, Román-Ivorra JA, Alonso A, Martín Mola E, Cantalejo M, Ercole L, Rivero N; study investigators.

Clin Exp Rheumatol. 2019 May-Jun;37(3):437-444. Epub 2018 Sep 17.

PMID: 30299241 **Free article**. Clinical Trial. Otettu 2.11.20

Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous **Tocilizumab** Following Single-Dose Administration in Patients With Active Rheumatoid **Arthritis** on Stable Methotrexate.

Paccaly AJ, Kovalenko P, Parrino J, Boyapati A, Xu C, van Hoogstraten H, Ishii T, Davis JD, DiCioccio AT.

J Clin Pharmacol. 2020 Jul 29. doi: 10.1002/jcph.1703. Online ahead of print.

PMID: 32726514 Otettu 2.11.20

[Comparisons of the outcomes between early and late **tocilizumab** treatment in systemic juvenile idiopathic arthritis.](#)

Pacharapakornpong T, Vallibhakara SA, Lerkvaleekul B, Vilaiyuk S.

Rheumatol Int. 2017 Feb;37(2):251-255. doi: 10.1007/s00296-016-3595-z. Epub 2016 Oct 31.

PMID:

27798725 Otettu 4.5.18

[Similar articles](#)

[Treatment of multicentric reticulohistiocytosis with **tocilizumab**.](#)

Pacheco-Tena C, Reyes-Cordero G, Ochoa-Albíztegui R, Ríos-Barrera V, González-Chávez SA. J Clin Rheumatol. 2013 Aug;19(5):272-6. doi: 10.1097/RHU.0b013e31829cf32b.

PMID:

23872542

[PubMed - indexed for MEDLINE] Otettu

[Related citations](#)

[Cogan's syndrome: new therapeutic approaches in the biological era.](#)

Padoan R, Cazzador D, Pendolino AL, Felicetti M, De Pascalis S, Zanoletti E, Bovo R, Martini A, Schiavon F.

Expert Opin Biol Ther. 2019 Aug;19(8):781-788. doi: 10.1080/14712598.2019.1611779. Epub 2019 May 6.

PMID: 31056972 Review. Otta M

[Reversible Dilated Cardiomyopathy in a Male Patient With Rheumatoid Arthritis: A Case Report.](#)

Padovani CM, Tao J, Fardos MI, Brecher L.

Cureus. 2024 Oct 23;16(10):e72216. doi: 10.7759/cureus.72216. eCollection 2024 Oct.

PMID: 39583411 [Free PMC article.](#) [Otettu 14.1.25](#)

[Predictors of Mortality in Tocilizumab-Treated Severe COVID-19.](#)

Pagkratis K, Chrysikos S, Antonakis E, Pandi A, Kostis CN, Markatis E, Hillas G, Digalaki A, Koukidou S, Chaini E, Afthinos A, Dimakou K, Papanikolaou IC.

Vaccines (Basel). 2022 Jun 20;10(6):978. doi: 10.3390/vaccines10060978.

PMID: 35746585 [Free PMC article.](#) [Otettu 16.7.22](#)

747.

[Value of \(18\)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.](#)

Palard-Novello X, Querellou S, Gouillou M, Saraux A, Marhadour T, Garrigues F, Abgral R, Salaün PY, Devauchelle-Pensec V.

Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):773-9. doi: 10.1007/s00259-015-3287-z. Epub 2016 Jan 11.

PMID: [Otettu 26.4.2018](#)

26753600

[Similar articles](#)

[Tocilizumab-induced psoriasiform rash in rheumatoid arthritis.](#)

Palmou-Fontana N, Sánchez Gaviño JA, McGonagle D, García-Martínez E, Iñiguez de Onzoño Martín L.

Dermatology. 2014;228(4):311-3. doi: 10.1159/000362266. Epub 2014 Jun 12.

PMID:

24942661

[PubMed - in process] ei ole M

[Related citations](#)

[Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis.](#)

Palmowski A, Buttgereit F.

Curr Rheumatol Rep. 2020 Oct 12;22(12):85. doi: 10.1007/s11926-020-00961-0.

PMID: 33047263 [Free PMC article.](#) Otettu 9.1.21

[Unraveling the Complexities of Idiopathic Multicentric Castleman Disease and Its Multi-systemic Associations: A Case Report.](#)

Palvia AR, Saha P, Nandi AR, Damera AR, Suresh A.

Cureus. 2024 Jul 19;16(7):e64935. doi: 10.7759/cureus.64935. eCollection 2024 Jul.

PMID: 39161530 [Free PMC article.](#) Otettu 16.11.24

Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience.

Panopoulos ST, Tektonidou MG, Bournia VK, Arida A, Sfrikakis PP.

J Rheumatol. 2022 Jan;49(1):68-73. doi: 10.3899/jrheum.210273. Epub 2021 Aug 15.

PMID: 34393104 Otta M

Cardiac magnetic resonance imaging before and after therapeutic interventions for systemic sclerosis-associated myocarditis.

Panopoulos S, Mavrogeni S, Vlachopoulos C, Sfrikakis PP.

Rheumatology (Oxford). 2023 Apr 3;62(4):1535-1542. doi: 10.1093/rheumatology/keac504.

PMID: 36083014 Otta M

Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort.

Panopoulos S, Chatzidionysiou K, Tektonidou MG, Bournia VK, Drosos AA, Liossis SC, Dimitroulas T, Sakkas L, Boumpas D, Voulgari PV, Daoussis D, Thomas K, Georgiopoulos G, Vosvotekas G, Garyfallos A, Sidiropoulos P, Bertias G, Vassilopoulos D, Sfrikakis PP.

Arthritis Res Ther. 2020 Mar 23;22(1):56. doi: 10.1186/s13075-020-2140-3.

PMID: 32293545 Free PMC article. Otettu 2.11.20

Mechanistic Insights into Cytokine Antagonist-Drug Interactions: A Physiologically Based Pharmacokinetic Modelling Approach with **Tocilizumab** as a Case Study.

Pan X, Liu C, Stader F, Derbalah A, Jamei M, Gardner I.

Pharmaceutics. 2025 Jul 10;17(7):896. doi: 10.3390/pharmaceutics17070896.

PMID: 40733104 [Free PMC article.](#) [Ota](#)

Tocilizumab plus Nintedanib for progressive interstitial lung disease in systemic sclerosis: a one-year observational study.

Panopoulos S, Tzilas V, Bournia VK, Tektonidou MG, Sfrikakis PP.

Rheumatol Int. 2024 Oct;44(10):1959-1966. doi: 10.1007/s00296-024-05695-1. Epub 2024 Aug 24.

PMID: 39180531 [Otta M](#)

Clinical and dermoscopic description of accelerated nodulosis after **tocilizumab** treatment for an isolated aortitis with coronary involvement.

Paolino G, Sartorelli S, Rizzo N, Tomelleri A, Campochiaro C, Pampena R, Dagna L, Mercuri SR.

Int J Dermatol. 2021 Mar 15. doi: 10.1111/ijd.15531. Online ahead of print.

PMID: 33723867 [Otettu 6.8.21](#)

[Impact of early treatment on the relapse-free survival and glucocorticoid dosing in giant cell arteritis: a retrospective cohort study.](#)

Papachristodoulou E, Kakoullis L, Sehra ST.

Clin Rheumatol. 2025 Aug;44(8):3277-3283. doi: 10.1007/s10067-025-07560-3. Epub 2025 Jul 5.

PMID: 40616748 Ota

[Tocilizumab in severe and refractory non-infectious uveitis.](#)

Papo M, Bielefeld P, Vallet H, Seve P, Wechsler B, Cacoub P, Le Hoang P, Papo T, Bodaghi B, Saadoun D.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S75-9. Epub 2014 Sep 30.

PMID:

25268663

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with **Tocilizumab** in Routine US Clinical Practice.

Pappas DA, Etzel CJ, Zlotnick S, Best J, Blachley T, Kremer JM.

Rheumatol Ther. 2019 Sep;6(3):421-433. doi: 10.1007/s40744-019-0162-6. Epub 2019 Jun 25.

PMID: 31240499 [Free PMC article.](#) Otettu 9.1.21

[Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients.](#)

Pappas DA, Reed G, Kane K, Curtis JR, Charles-Schoeman C, Giles JT, Kremer JM.

Semin Arthritis Rheum. 2024 Oct;68:152504. doi: 10.1016/j.semarthrit.2024.152504. Epub 2024 Jun 29.

PMID: 38991379 Otta M

Methotrexate Discontinuation and Dose Decreases After Therapy With **Tocilizumab**: Results From the Corrona Rheumatoid **Arthritis** Registry.

Pappas DA, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer JM.

Rheumatol Ther. 2020 Jun;7(2):357-369. doi: 10.1007/s40744-020-00200-z. Epub 2020 Mar 30.

PMID: 32232740 [Free PMC article.](#) Otettu 2.11.20

Effectiveness of **Tocilizumab** in Patients with Rheumatoid Arthritis Is Unaffected by Comorbidity Burden or Obesity: Data from a US Registry.

Pappas DA, Etzel CJ, Crabtree M, Blachley T, Best J, Zlotnick S, Kremer JM.

J Rheumatol. 2020 Oct 1;47(10):1464-1474. doi: 10.3899/jrheum.190282. Epub 2020 Jan 15.

PMID: 31941801 Otettu 9.1.21

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.

Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Puneekar R, Emeanuru K, Choi J, Boklage S, Kremer JM.

Ann Rheum Dis. 2021 Jan;80(1):96-102. doi: 10.1136/annrheumdis-2020-217209. Epub 2020 Jul 21.

PMID: 32719038 Otettu 9.1.21

Neutropenia During **Tocilizumab** Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic **Arthritis**.

Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz HI, Minden K, Onel K, Zemel L, Martin A, Koné-Paut I, Siamopoulou-Mavridou A, Silva CA, Porter-Brown B, Bharucha KN, Brunner HI, De Benedetti F; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).

J Rheumatol. 2019 Sep;46(9):1117-1126. doi: 10.3899/jrheum.180795. Epub 2019 Mar 1.

PMID: 30824645 Otettu 2.11.20

Impact of COVID-19 therapy on hyperglycemia.

Parise R, Deruiter J, Ren J, Govindarajulu M, Ramesh S, Nadar RM, Moore T, Dhanasekaran M.

Diab Vasc Dis Res. 2022 May-Jun;19(3):14791641221095091. doi:

10.1177/14791641221095091.

PMID: 35695412 [Free PMC article.](#) Otettu 16.7.22

[Update on tocilizumab in rheumatoid arthritis: a narrative review.](#)

Parisi S, Ditto MC, Ghellere F, Panaro S, Piccione F, Borrelli R, Fusaro E.

Front Immunol. 2025 Feb 24;16:1470488. doi: 10.3389/fimmu.2025.1470488. eCollection 2025.
PMID: 40066438 **Free PMC article**. Review. Otettu 30.3.25

[Interleukin-6 in the pathogenesis of rheumatoid arthritis.](#)

Park JY, Pillinger MH.

Bull NYU Hosp Jt Dis. 2007;65 Suppl 1:S4-10. Review.

PMID:

17708744

[PubMed - indexed for MEDLINE] ei oteta

[Free Article](#)

[Related citations](#)

Select item 177087411138.

[Left ventricular remodeling in rheumatoid arthritis patients without clinical heart failure.](#)

Park E, Ito K, Depender C, Giles JT, Bathon J.

Arthritis Res Ther. 2023 Jul 21;25(1):124. doi: 10.1186/s13075-023-03113-8.

PMID: 37480064 **Free PMC article**. Otettu 30.8.23

[The Aftermath of Tapering **Tocilizumab** After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study.](#)

Park JW, Kim MJ, Kim HA, Kim JH, Lee EB, Shin K.

Front Med (Lausanne). 2022 Feb 8;9:839206. doi: 10.3389/fmed.2022.839206. eCollection 2022.

PMID: 35211491 [Free PMC article.](#) Otettu 16.7.22

[Adult-onset Still's Disease after BNT162b2 mRNA COVID-19 Vaccine.](#)

Park SY, Lee KH.

J Korean Med Sci. 2021 Dec 27;36(50):e344. doi: 10.3346/jkms.2021.36.e344.

PMID: 34962116 [Free PMC article.](#) Otettu 16.7.22

Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic **arthritis**: a case-based review.

Park EH, Lee EY, Shin K, Kim HA.

Rheumatol Int. 2020 May;40(5):791-798. doi: 10.1007/s00296-019-04456-9. Epub 2019 Oct 9.

PMID: 31598752 Review. Otettu 2.11.20

[Clinical use of biologics in vasculitis syndromes.](#)

Paroli M.

Biologics. 2012;6:371-8. doi: 10.2147/BTT.S37537. Epub 2012 Oct 25.

PMID:

23118526 Otettu 24.7.15

[PubMed]

[Free PMC Article](#)

[Related citations](#)

[Management of calcium pyrophosphate crystal deposition disease: A systematic review.](#)

Parperis K, Papachristodoulou E, Kakoullis L, Rosenthal AK.

Semin Arthritis Rheum. 2020 Dec 21;51(1):84-94. doi: 10.1016/j.semarthrit.2020.10.005. Online ahead of print.

PMID: 33360232 Review. Otettu 9.1.21

[Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.](#)

Pasadhika S, Rosenbaum JT.

Biologics. 2014 Feb 15;8:67-81. doi: 10.2147/BTT.S41477. eCollection 2014. Review.

PMID:

24600203 Otettu 24.7.15

[PubMed]

[Free PMC Article](#)

[Related citations](#)

[Comparative efficacy of **tocilizumab**, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.](#)

Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM.

Int J Rheum Dis. 2016 Nov;19(11):1093-1102. doi: 10.1111/1756-185X.12845. Epub 2016 Mar 27.

PMID: Otettu 26.4.2018

27018857

[Similar articles](#)

Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy.

Pascual-Camps I, Molina-Pallete R, Bort-Martí MA, Todolí J, España-Gregori E.

Orbit. 2018 Feb 8;1-4. doi: 10.1080/01676830.2018.1435694. [Epub ahead of print]

PMID:

29420104 Otettu 26.4.2018

[Similar articles](#)

Dramatic response to delayed treatment with **tocilizumab in new-onset refractory status epilepticus.**

Pasqualini N, Falcicchio G, Vogrig A, Pellicciari R, Defazio G, Gelormini D, Liviero MC, Gottin L, Bonetti B, Zivelonghi C, Ferlisi M, Zanoni T.

Neurol Sci. 2025 Mar 18. doi: 10.1007/s10072-025-08108-8. Online ahead of print.

PMID: 40100558 Otta M

Tocilizumab versus methotrexate in moderate to severe rheumatoid arthritis.

Patel AM, Moreland LW.

Curr Rheumatol Rep. 2009 Oct;11(5):313-4. No abstract available.

PMID:

19772824 [Kokotekstinä](#) OK

[PubMed]

[Free PMC Article](#)

[Related citations](#)

[The Role of Biologics in Rheumatoid Arthritis: A Narrative Review.](#)

Patel JP, Konanur Srinivasa NK, Gande A, Anusha M, Dar H, Baji DB.

Cureus. 2023 Jan 3;15(1):e33293. doi: 10.7759/cureus.33293. eCollection 2023 Jan.

PMID: 36606106 [Free PMC article](#). Review. Otettu 3.6.23

[The Effects of Daily Prednisone and **Tocilizumab** on Hemoglobin A1c During the Treatment of Giant Cell Arteritis.](#)

Patel NJ, Tozzo V, Higgins JM, Stone JH.

Arthritis Rheumatol. 2023 Apr;75(4):586-594. doi: 10.1002/art.42405. Epub 2023 Jan 25.

PMID: 36383175 Clinical Trial. Otettu 3.6.23

[Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of **tocilizumab** therapy.](#)

Patel AM, Moreland LW.

Drug Des Devel Ther. 2010 Oct 1;4:263-78. doi: 10.2147/DDDT.S14099. Review.

PMID:

21116333

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

[The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial.](#)

Patel NJ, Fu X, Zhang Y, Unizony SH, Wallace ZS, Choi HK, Stone JH.

Rheumatol Ther. 2021 Dec 25. doi: 10.1007/s40744-021-00411-y. Online ahead of print.
PMID: 34954809 [Free article](#). Otettu 16.7.22

Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis.

Patsalos O, Dalton B, Himmerich H.

Int J Mol Sci. 2020 Aug 31;21(17):6290. doi: 10.3390/ijms21176290.

PMID: 32878032 [Free PMC article](#). Otettu 9.1.21

[Tocilizumab increases EPC regeneration in rheumatoid arthritis.](#)

Patschan S, Nemirovsky K, Henze E, Scholze J, Müller GA, Patschan D.

Scand J Rheumatol. 2014;43(6):528-30. doi: 10.3109/03009742.2014.926985. Epub 2014 Sep 15. No abstract available.

PMID:

25222920

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

8.

[Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.](#)

Paul-Pletzer K.

Drugs Today (Barc). 2006 Sep;42(9):559-76. Review.

PMID:

17028666

[PubMed - indexed for MEDLINE] ei ole M

[Related citations](#)

Risk of serious infections in **tocilizumab** versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.

Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, Sarsour K, Schneeweiss S, Kim SC.

Ann Rheum Dis. 2019 Apr;78(4):456-464. doi: 10.1136/annrheumdis-2018-214367. Epub 2019 Jan 24.

PMID: 30679153 Otettu 2.11.20

[Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.](#)

Pavelka K, Kavanaugh AF, Rubbert-Roth A, Ferraccioli G.

Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v12-21. doi: 10.1093/rheumatology/kes111. Review.

PMID:

22718922

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

518.

[Tocilizumab in glucocorticoid-naïve large-vessel vasculitis.](#)

Pazzola G, Padovano I, Boiardi L, Versari A, Pipitone N, Catanoso M, Pulsatelli L, Meliconi R, Salvarani C.

Clin Exp Rheumatol. 2013 Jan-Feb;31(1 Suppl 75):S59-61. Epub 2013 Jan 9.

PMID:

23306184

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

Granuloma annulare development in a patient with rheumatoid **arthritis** treated with **tocilizumab**: case-based review.

Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA.

Rheumatol Int. 2019 Feb;39(2):353-357. doi: 10.1007/s00296-018-4212-0. Epub 2018 Dec 7.

PMID: 30523477 Review. Otettu 2.11.20

Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients.

Pelechas E, Drossou V, Voulgari PV, Drosos AA.

Mediterr J Rheumatol. 2022 Mar 31;33(1):68-74. doi: 10.31138/mjr.33.1.68. eCollection 2022 Mar.

PMID: 35611100 [Free PMC article.](#) Otta M

Re: Leclercq et al.: Anti-tumor necrosis factor- α versus **tocilizumab** in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network (Ophthalmology. 2022;129:520-529).

Pépin F, Niederer RL.

Ophthalmology. 2022 Jul;129(7):e77. doi: 10.1016/j.ophtha.2022.02.019. Epub 2022 Mar 25.

PMID: 35346510 Otettu 17.7.22

[Giant cell arteritis.](#)

Pepper K.

Postgrad Med. 2023 Jan;135(sup1):22-32. doi: 10.1080/00325481.2023.2190288. Epub 2023 Apr 6.

PMID: 37021621 Review. Otta M

[A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature.](#)

Perdan-Pirkmajer K, Praprotnik S, Tomšič M.

Clin Rheumatol. 2010 Dec;29(12):1465-7. doi: 10.1007/s10067-010-1553-9. Epub 2010 Aug 24. Review.

PMID:

20734215

[PubMed - indexed for MEDLINE] Otettu 2.6.15 OK

[Related citations](#)

[Systematic Review of Adverse Events of IL-1 and IL-6 Inhibitor Use in Pediatrics.](#)

Perera A, Chugh N, Garcia-Bournissen F.

J Pediatr Pharmacol Ther. 2025 Apr;30(2):152-169. doi: 10.5863/1551-6776-30.2.152. Epub 2025 Apr 14.

PMID: 40717752 Free PMC article. Ota

Steroid-Resistant Graves' Orbitopathy Treated with **Tocilizumab** in Real-World Clinical Practice: A 9-Year Single-Center Experience.

Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, Prada-Ramallal G.

J Clin Med. 2021 Feb 11;10(4):706. doi: 10.3390/jcm10040706.

PMID: 33670151 [Free PMC article](#). Otettu 6.8.21

Efficacy of **tocilizumab** in patients with moderate to severe corticosteroid resistant Graves' orbitopathy: A randomized clinical trial.

Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Lopez AR, Rodríguez Alvarez FM, Castillo Laguarda JM, Del Estad Cabello A, Sorroche MG, España Gregori E, Sales-Sanz M; **Tocilizumab** in Graves Orbitopathy Study Group.

Am J Ophthalmol. 2018 Aug 3. pii: S0002-9394(18)30431-8. doi: 10.1016/j.ajo.2018.07.038. [Epub ahead of print]

PMID:

30081019 Otettu 25.9.18

[Similar articles](#)

Cost-effectiveness analysis of subcutaneous biosimilar **tocilizumab** in patients with rheumatoid arthritis in Spain.

Pérez-Ruiz F, Crespo-Diz C, Schoenenberger-Arnaiz JA, Cerezales M, Crespo C, Guigini MA, Peinado-Fabregat JI, Climente-Martí M.

Farm Hosp. 2024 Dec 14;S1130-6343(24)00187-9. doi: 10.1016/j.farma.2024.11.004. Online ahead of print.

PMID: 39675937 [Free article](#). English, Spanish. Otettu 14.2.25

[Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line **tocilizumab** monotherapy: a case report.](#)

Perrotta FM, Fici M, Guerra G, Brunese L, Salvarani C, Lubrano E.

Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):226-227. Epub 2017 Apr 20. No abstract available.

PMID:

28466807 Otettu 5.4.18

[Similar articles](#)

[Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with **tocilizumab** in clinical practice.](#)

Pers YM, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, Mercier G, Pallot Prades B, Wendling D, Gaudin P, Jorgensen C, Marotte H, Maillefert JF.

Rheumatology (Oxford). 2014 Jan;53(1):76-84. doi: 10.1093/rheumatology/ket301. Epub 2013 Sep 19.

PMID:

24056521

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

108.

[Efficacy and safety of **tocilizumab** in elderly patients with rheumatoid arthritis.](#)

Pers YM, Schaub R, Constant E, Lambert J, Godfrin-Valnet M, Fortunet C, Bourichi W, Prades BP, Wendling D, Gaudin P, Jorgensen C, Maillefert JF, Marotte H.

Joint Bone Spine. 2015 Jan;82(1):25-30. doi: 10.1016/j.jbspin.2014.07.010. Epub 2014 Sep 17.

PMID:

25241333

[PubMed - in process] Otettu 2.6.15

[Related citations](#)

74.

[Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient.](#)

Pers YM, Godfrin-Valnet M, Lambert J, Fortunet C, Constant E, Mura T, Pallot-Prades B, Jorgensen C, Maillefert JF, Marotte H, Wendling D, Gaudin P.

J Rheumatol. 2015 Apr;42(4):580-4. doi: 10.3899/jrheum.140673. Epub 2015 Feb 1.

PMID:

25641885 Otettu 2.6.15

[Related citations](#)

.

[Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients.](#)

Pesce B, Soto L, Sabugo F, Wurmman P, Cuchacovich M, López MN, Sotelo PH, Molina MC, Aguillón JC, Catalán D.

Clin Exp Immunol. 2013 Mar;171(3):237-42. doi: 10.1111/cei.12017.

PMID:

23379428

[PubMed - indexed for MEDLINE] [Kokotekstinä](#) Otettu 25.7.15

[Free PMC Article](#)

[Related citations](#)

Select item 23378927504.

Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid **Arthritis** Treated with Subcutaneous **Tocilizumab**: The COMP-ACT MRI Substudy. Peterfy C, Kremer J, Rigby W, Singer N, Birchwood C, Gill D, Reiss W, Pei J, Michalska M. J Rheumatol. 2020 Mar;47(3):325-332. doi: 10.3899/jrheum.180953. Epub 2019 Jun 1. PMID: 31154414 [Free article](#). Otettu 2.11.20

Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid **arthritis** treated with **tocilizumab**'. Pethoe-Schramm A, Devenport J, Reiss W. Ann Rheum Dis. 2020 Jul 31;annrheumdis-2020-218365. doi: 10.1136/annrheumdis-2020-218365. Online ahead of print. Otettu 2.11.20

[Treatment of relapsing polychondritis: a systematic review.](#) Petitdemange A, Sztejkowski C, Damian L, Martin T, Mouthon L, Amoura Z, Cutolo M, Burmester GR, Fonseca JE, Rednic S, Arnaud L. Clin Exp Rheumatol. 2022 Jan 28. Online ahead of print. PMID: 35238756 Review. Otettu 16.7.22

Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis. Petro AD, Dougherty J, England BR, Sayles H, Duryee MJ, Hunter CD, Kremer JM, Pappas DA, Robinson WH, Curtis JR, Thiele GM, Mikuls TR.

Int Immunopharmacol. 2020 Dec 23;91:107260. doi: 10.1016/j.intimp.2020.107260. Online ahead of print.

PMID: 33360371 Otta M

[Limb arteries involvement assessed by FDG/PET CT at diagnosis of giant cell arteritis and risk of relapse: An observational study.](#)

Peyrac G, Mageau A, Gaudemer A, Benali K, Rohmer J, Alexandra JF, Strukov A, Ottaviani S, Papo T, Sacre K.

Joint Bone Spine. 2024 Sep;91(5):105734. doi: 10.1016/j.jbspin.2024.105734. Epub 2024 Apr 15.

PMID: 38631525 [Free article.](#) Otettu 26,11,24

[Multiple upper gastrointestinal perforations in a 15-year-old patient treated with tocilizumab.](#)

Pfeil J, Grulich-Henn J, Wenning D, Breil T, Günther P, Lutz T.

Rheumatology (Oxford). 2014 Sep;53(9):1713-4. doi: 10.1093/rheumatology/keu032. Epub 2014 Mar 12. No abstract available.

PMID:

24625503

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

[The Treatment of Giant Cell Arteritis in Different Clinical Settings.](#)

Pfeil A, Oelzner P, Hellmann P.

Front Immunol. 2019 Jan 24;9:3129. doi: 10.3389/fimmu.2018.03129. eCollection 2018.
PMID: 30733723 **Free PMC article.** Otettu 9.1.21

[Tocilizumab in giant cell arteritis].

Pflugfelder J.

Z Rheumatol. 2017 Feb;76(1):87-88. doi: 10.1007/s00393-016-0243-7. German. No abstract available.

PMID:

27904995 Otettu 26.4.2018

[Similar articles](#)

943.

Tocilizumab: therapy and safety management.

Pham T, Claudepierre P, Constantin A, de Bandt M, Fautrel B, Gossec L, Gottenberg JE, Goupille P, Guillaume S, Hachulla E, Masson C, Morel J, Puéchal X, Saraux A, Schaeffer T, Wendling D, Bruckert E, Pol S, Mariette X, Sibilia J; Club Rhumatismes et Inflammation (CRI). Joint Bone Spine. 2010 Jun;77 Suppl 1:S3-100. doi: 10.1016/S1297-319X(10)70001-4. Epub 2010 Jun 17.

PMID:

20610315

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

Anti-interleukin-6 receptor therapy with **tocilizumab** for refractory pseudophakic cystoid macular edema.

Pham BH, Hien DL, Matsumiya W, Tuong Ngoc TT, Doan HL, Akhavanrezayat A, Yaşar Ç, Nguyen HV, Halim MS, Nguyen QD.

Am J Ophthalmol Case Rep. 2020 Aug 20;20:100881. doi: 10.1016/j.ajoc.2020.100881. eCollection 2020 Dec.

PMID: 32875161 [Free PMC article](#). [Otettu 9.1.21](#)

[Giant Cell Arteritis With Atypical Features: Acute Vision Loss and Marked Eosinophilia Mimicking Systemic Vasculitis.](#)

Phrathep D, Billings SA, Khan H, Patel P, Mohseni M.

Cureus. 2025 Jun 17;17(6):e86195. doi: 10.7759/cureus.86195. eCollection 2025 Jun.

PMID: 40677452 [Free PMC article](#). [Ota](#)

[Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents.](#)

Picchianti-Diamanti A, Aiello A, De Lorenzo C, Migliori GB, Goletti D.

Front Immunol. 2025 Feb 3;16:1494283. doi: 10.3389/fimmu.2025.1494283. eCollection 2025.

PMID: 39963138 [Free PMC article](#). Review. [Otettu 27.2.25](#)

[An update on the clinical approach to giant cell arteritis.](#)

Piccus R, Hansen MS, Hamann S, Mollan SP.

Clin Med (Lond). 2022 Mar;22(2):107-111. doi: 10.7861/clinmed.2022-0041.

PMID: 35304369 [Free PMC article](#). [Otettu 17.7.22](#)

Effect of **Tocilizumab** on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study.

Pierini FS, Botta E, Soriano ER, Martin M, Boero L, Meroño T, Saez MS, Lozano Chiappe E, Cerda O, Citera G, Gandino I, Rosa J, Sorroche P, Kontush A, Brites F.

Rheumatol Ther. 2021 Jun;8(2):803-815. doi: 10.1007/s40744-021-00304-0. Epub 2021 Apr 2.

PMID: 33811316 [Free PMC article.](#) [Otettu 6.8.21](#)

Treatment Consistent with Idiopathic Multicentric Castleman Disease Guidelines is Associated with Improved Outcomes.

Pierson SK, Lim MS, Srkalovic G, Brandstadter JD, Sarmiento Bustamante M, Shyamsundar S, Mango N, Lavery C, Austin B, Alapat D, Lechowicz MJ, Bagg A, Li H, Casper C, van Rhee F, Fajgenbaum DC.

Blood Adv. 2023 Sep 1:bloodadvances.2023010745. doi: 10.1182/bloodadvances.2023010745. Online ahead of print.

PMID: 37656441 [Otettu 9.10.23](#)

Myocarditis as the Initial Presentation of a Refractory Adult-Onset Still's Disease.

Pina Gonçalves N, Lourenço MH, Albuquerque F, Gonçalves MJ, Falcão S.

Cureus. 2022 Oct 1;14(10):e29821. doi: 10.7759/cureus.29821. eCollection 2022 Oct.

PMID: 36337832 [Free PMC article.](#) [Otettu 3.6.23](#)

Effectiveness of **Tocilizumab** in the Treatment of Fasciitis with Eosinophilia: Two Case Reports.
Pinheiro G, Costa AR, Campar A, Mendonça T.
Eur J Case Rep Intern Med. 2020 Mar 2;7(4):001485. doi: 10.12890/2020_001485. eCollection 2020.
PMID: 32309257 [Free PMC article.](#) Otettu 9.1.21

[Biotechnological therapeutic in Juvenile Idiopathic Arthritis: Pathophysiological implications and targeted therapies.](#)
Pinto AM, Ascensão I, Rodrigues M, Brito I.
ARP Rheumatol. 2023 Oct-Dec;2(4):299-306.
PMID: 38174749 [Free article.](#) English. Otettu 7.3.24

.
[Tocilizumab in a patient with tophaceous gout resistant to treatment.](#)
Pinto JL, Mora GE, Fernández-Avila DG, Gutiérrez JM, Díaz MC; Grupo Javeriano de Investigación en Enfermedades Reumáticas.
Reumatol Clin. 2013 May-Jun;9(3):178-80. doi: 10.1016/j.reuma.2012.06.009. Epub 2012 Oct 31. English, Spanish.
PMID:
23122521 Otettu 5.4.18
[PubMed - indexed for MEDLINE] [Kokotekstinä](#)
[Free Article](#)
[Related citations](#)

Select item 23118526573.

115.

[Primary Care Vasculitis: Polymyalgia Rheumatica and Giant Cell Arteritis.](#)

Pioro MH.

Prim Care. 2018 Jun;45(2):305-323. doi: 10.1016/j.pop.2018.02.007. Review.

PMID:

29759126 ei oteta

[Similar articles](#)

462.

[Update on polymyalgia rheumatica.](#)

Pipitone N, Salvarani C.

Eur J Intern Med. 2013 Oct;24(7):583-9. doi: 10.1016/j.ejim.2013.03.003. Epub 2013 Apr 8.
Review.

PMID:

23579169

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

Tocilizumab in a patient with newly diagnosed rheumatoid **arthritis** secondary to checkpoint inhibitor therapy.

Pirker I, Rubbert-Roth A, von Kempis J, Fehr M, Neumann T.

Clin Exp Rheumatol. 2020 May-Jun;38(3):573-574. Epub 2020 Jan 28.

PMID: 31994482 **Free article.** Otettu 2.11.20

Efficacy and harms of **tocilizumab** for the treatment of COVID-19 patients: A systematic review and meta-analysis.

Piscoya A, Parra Del Riego A, Cerna-Viacava R, Rocco J, Roman YM, Escobedo AA, Pasupuleti V, White CM, Hernandez AV.

PLoS One. 2022 Jun 3;17(6):e0269368. doi: 10.1371/journal.pone.0269368. eCollection 2022.

PMID: 35657993 [Free PMC article](#). Otettu 16.7.22

In glucocorticoid-dependent polymyalgia rheumatica, **tocilizumab** improved a composite clinical outcome at 24 wk.

Pisetsky DS.

Ann Intern Med. 2023 Jan;176(1):JC5. doi: 10.7326/J22-0107. Epub 2023 Jan 3.

PMID: 36592464 Clinical Trial. Otta M

[Relapsing polychondritis: response to **tocilizumab** and association with colitis.](#)

Plunkett M, Lamont D, Brooker J, White D.

J Clin Rheumatol. 2013 Oct;19(7):415-7. doi: 10.1097/RHU.0b013e3182a6fec9. No abstract available.

PMID:

24048111

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

1084.

[Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis.](#)

Plushner SL.

Ann Pharmacother. 2008 Nov;42(11):1660-8. doi: 10.1345/aph.1L268. Epub 2008 Oct 28.

Review.

PMID:

18957621

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

[Precision medicine in rheumatology: are we getting closer?](#)

Poddubnyy D.

Lancet. 2021 Jan 23;397(10271):258-259. doi: 10.1016/S0140-6736(20)32652-0.

PMID: 33485433 Otta M

[Successful Tocilizumab Treatment for Scleritis.](#)

Poelman HJ, Van Daele PLA, Rothova A.

Ocul Immunol Inflamm. 2020;28(2):285-287. doi: 10.1080/09273948.2019.1617885. Epub 2019 Aug 14.

PMID: 31411511 Otta M

[Highlights from the breakout session: imaging in disease assessment.](#)

Ponte C, Schmidt WA, Blockmans D.

Rheumatology (Oxford). 2025 Mar 1;64(Supplement_1):i123-i125. doi: 10.1093/rheumatology/keae408.
PMID: 40071407 Review. Otettu 30.3.25

[Giant cell arteritis: Current treatment and management.](#)

Ponte C, Rodrigues AF, O'Neill L, Luqmani RA.

World J Clin Cases. 2015 Jun 16;3(6):484-94. doi: 10.12998/wjcc.v3.i6.484. Review.

PMID:

26090367 Otettu 24.7.15

[Free PMC Article](#)

[Similar articles](#)

[State-of-the-art evidence in the treatment of systemic sclerosis.](#)

Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T.

Nat Rev Rheumatol. 2023 Apr;19(4):212-226. doi: 10.1038/s41584-023-00909-5. Epub 2023 Feb 27.

PMID: 36849541 [Free PMC article.](#) Otettu 3.6.23

[Etiologies and management of haemophagocytic lymphohistiocytosis: is it time for an updated protocol and targeted treatments?](#)

Posas-Mendoza TF, McLeod C, Davis W, Zakem J, Quinet R.

Rheumatology (Oxford). 2020 Dec 11;keaa741. doi: 10.1093/rheumatology/keaa741. Online ahead of print.

PMID: 33313881 Otettu 9.1.21

[CSF IL-6 in children with neuroinflammatory conditions.](#)

Pozzilli V, Thambiliyagodage MP, Mankad K, Worth A, Brogan P, Ghorashian S, Bamford A, Hemingway C, Kaliakatsos M, Gilmour K, Hacoheh Y.

Eur J Paediatr Neurol. 2025 Jul 30;58:42-49. doi: 10.1016/j.ejpn.2025.07.013. Online ahead of print.

PMID: 40752430 Ota

[Giant Cell Arteritis: Practical Pearls and Updates.](#)

Pradeep S, Smith JH.

Curr Pain Headache Rep. 2018 Jan 17;22(1):2. doi: 10.1007/s11916-018-0655-y. Review.

PMID:

29344777 ei ole M

[Similar articles](#)

[Treatment of systemic sclerosis-associated interstitial lung disease\].](#)

Prasse A, Bonella F, Müller-Ladner U, Witte T, Hunzelmann N, Distler J.

Z Rheumatol. 2020 Apr;79(3):294-303. doi: 10.1007/s00393-019-00724-y.

PMID: 31754786 Otettu 9.1.21

1010.

[Tocilizumab: new drug. Rheumatoid arthritis: another 'mab'. no therapeutic advantage.](#)

[No authors listed]

Prescrire Int. 2009 Oct;18(103):198-201.

PMID:

19882783

[PubMed - indexed for MEDLINE] ei ole M

[Related citations](#)

[Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in **tocilizumab**-treated patients.](#)

Prieto-González S, Terrades-García N, Corbera-Bellalta M, Planas-Rigol E, Miyabe C, Alba MA, Ponce A, Tavera-Bahillo I, Murgia G, Espígol-Frigolé G, Marco-Hernández J, Hernández-Rodríguez J, García-Martínez A, Unizony SH, Cid MC.

RMD Open. 2017 Dec 22;3(2):e000570. doi: 10.1136/rmdopen-2017-000570. eCollection 2017.

PMID:

29299342 Otettu 5.4.18

[Free PMC Article](#)

[Similar articles](#)

Predicting the risk of relapse in polymyalgia rheumatica: novel insights.

Prieto-Peña D, Castañeda S, Atienza-Mateo B, Blanco R, González-Gay MA.

Expert Rev Clin Immunol. 2021 Mar;17(3):225-232. doi: 10.1080/1744666X.2021.1890032. Epub 2021 Apr 9.

PMID: 33570454 Otta M

Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review.

Prieto-Peña D, Bernabeu P, Vela P, Narváez J, Fernández-López JC, Freire-González M, González-Álvarez B, Solans-Laqué R, Callejas Rubio JL, Ortego N, Fernández-Díaz C, Rubio E, García-Morillo S, Minguez M, Fernández-Carballido C, de Miguel E, Melchor S, Salgado E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Manrique S, Romero-Gómez C, Moya P, Álvarez-Rivas N, Mendizabal J, Ortiz-Sanjuán F, Pérez de Pedro I, Alonso-Valdivielso JL, Perez-Sanchez L, Roldán R, Fernandez-Llanio N, Gómez de la Torre R, Suarez S, Montesa Cabrera MJ, Delgado Sánchez M, Loricera J, Atienza-Mateo B, Castañeda S, González-Gay MA, Blanco R.

Ther Adv Musculoskelet Dis. 2021 Jun 18;13:1759720X211020917. doi: 10.1177/1759720X211020917. eCollection 2021.

PMID: 34211589 [Free PMC article](#). Otettu 6.8.21

Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in **tocilizumab**-treated patients with large-vessel giant cell arteritis.

Prieto Peña D, Martínez-Rodríguez I, Atienza-Mateo B, Calderón-Goercke M, Banzo I, González-Vela MC, Castañeda S, Llorca J, González-Gay MÁ, Blanco R.

Clin Exp Rheumatol. 2020 Nov 27. Online ahead of print.

PMID: 33253103 Otta M

JAK Inhibitor Effectiveness in Giant-Cell Arteritis With Large-Vessel Involvement Assessed by 18F-FDG PET-CT.

Prigent K, Aouba A, Aide N, de Boysson H.

Clin Nucl Med. 2022 Mar 1;47(3):234-235. doi: 10.1097/RLU.0000000000003913.

PMID: 34653043 Otta M

.
[A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis.](#)

Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfrikakis PP.

Atherosclerosis. 2011 Dec;219(2):734-6. doi: 10.1016/j.atherosclerosis.2011.09.015. Epub 2011 Sep 16.

PMID:

21968316

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

1.

[The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tocilizumab.](#)

Provan SA, Berg IJ, Hammer HB, Mathiessen A, Kvien TK, Semb AG.

PLoS One. 2015 Jun 26;10(6):e0130709. doi: 10.1371/journal.pone.0130709. eCollection 2015.

PMID:

26114946 Otettu 24.7.15

[Free Article](#)

[Similar articles](#)

[Tocilizumab in refractory adult Still's disease.](#)

Puéchal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, Kahn JE, Lequen L, Longy-Boursier M, Perdriger A, Schaefferbeke T, Toussierot E, Sibilia J; Club Rhumatismes Et Inflammation.

Arthritis Care Res (Hoboken). 2011 Jan;63(1):155-9. doi: 10.1002/acr.20319.

PMID:

20740616

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Related citations](#)

Compared efficacy of rituximab, abatacept, and **tocilizumab** in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis.

Pugliesi A, de Oliveira AB, Oliveira AB, Xavier R, Bertolo MB, Gonzalez-Gay MA, Citera G, de Carvalho LSF.

Adv Rheumatol. 2023 Jul 6;63(1):30. doi: 10.1186/s42358-023-00298-z.

PMID: 37415193 Otettu 30.8.23

[Cardiovascular safety of the class of JAK inhibitors or **tocilizumab** compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials.](#)

Pugliesi A, Oliveira DGC, Filho VAS, Machado JO, Pereira AG, Bichuette JCS, Sachetto Z, de Carvalho LSF, Bertolo MB.

Semin Arthritis Rheum. 2024 Oct 2;69:152563. doi: 10.1016/j.semarthrit.2024.152563. Online ahead of print.

PMID: 39383617 Review. Otta M

Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy.

Pulito-Cueto V, Remuzgo-Martínez S, Genre F, Calvo-Alén J, Aurrecoechea E, Llorente I, Triguero-Martinez A, Blanco R, Llorca J, Ruiz-Lucea E, Rivera-García N, Gualillo O, López-Mejías R, Castañeda S, González-Gay MA.

Clin Exp Rheumatol. 2021 Jul 7. Online ahead of print.

PMID: 34251326 Otta M

Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis.

Pulito-Cueto V, Remuzgo-Martínez S, Genre F, Calvo-Alén J, Aurrecoechea E, Llorente I, Triguero-Martinez A, Blanco R, Llorca J, Ruiz-Lucea E, Rivera-García N, Gualillo O, López-Mejías R, Castañeda S, González-Gay MA.

Clin Exp Rheumatol. 2020 Nov-Dec;38(6):1201-1205. Epub 2020 May 20.

PMID: 32452351 Otettu 9.1.21

Real-World Dose Modification Patterns of Subcutaneous **Tocilizumab** Among Patients with Rheumatoid **Arthritis**.

Punekar R, Choi J, Boklage S, Iglesias-Rodriguez M, Nola K.

Am Health Drug Benefits. 2019 Dec;12(8):400-409.

PMID: 32030116 Free PMC article. Otettu 2.11.20

[Early versus escalation treatment of **tocilizumab** in neuromyelitis optica spectrum disorder: a retrospective study.](#)

Qi Y, Liu R, Zhao Y, Zhang L, Zhang Q, Li L, Yang C, Yang L, Jiang W.

Neurol Sci. 2025 Feb 14. doi: 10.1007/s10072-025-08046-5. Online ahead of print.

PMID: 39951176 Otta M

[Successful **tocilizumab** treatment for rapidly progressive interstitial lung disease with anti-MDA5-positive juvenile dermatomyositis: a case report and literature review.](#)

Qiu L, Shao X, Ma L, Fan Z, Yu H.

Front Pediatr. 2024 Nov 27;12:1497168. doi: 10.3389/fped.2024.1497168. eCollection 2024.

PMID: 39664278 [Free PMC article.](#) Otettu 14.2.25

[Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study.](#)

Quartuccio L, Isola M, Bruno D, Treppo E, Gigante L, Angelotti F, Capecchi R, Vitiello G, Cavallaro E, Tavoni A, Bosello SL, Cammelli D, De Vita S, Gremese E.

J Transl Autoimmun. 2020 Nov 28;3:100072. doi: 10.1016/j.jtauto.2020.100072. eCollection 2020.

PMID: 33305250 [Free PMC article.](#) Otettu 9.1.21

[Faster steroid-free remission with **tocilizumab** compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres.](#)

Quartuccio L, Treppo E, De Martino M, Pillon M, Perniola S, Bruno D, Isola M, Gremese E.
Intern Emerg Med. 2024 Nov;19(8):2177-2184. doi: 10.1007/s11739-024-03722-4. Epub 2024 Aug 2.

PMID: 39093541 [Free PMC article.](#) otettu 26.11.24

[Subcutaneous **Tocilizumab** May Be Less Effective than Intravenous **Tocilizumab** in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis.](#)

Quesada-Masachs E, Caballero CM.

J Rheumatol. 2017 Feb;44(2):260-261. doi: 10.3899/jrheum.160908. No abstract available.

PMID:

28148759 Otettu 26.4.2018

[Similar articles](#)

[Life after **tocilizumab** given for giant cell arteritis: a patient survey and argument for re-treatment.](#)

Quick V, Benson F, Mackie SL.

Rheumatol Adv Pract. 2024 Apr 17;8(2):rkae054. doi: 10.1093/rap/rkae054. eCollection 2024.

PMID: 38725437 [Free PMC article.](#) Otettu 26.11.24

[Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: Two cases report.](#)

Quilis N, Andrés M, Vela P, Pascual E.

Joint Bone Spine. 2017 May 9. pii: S1297-319X(17)30090-8. doi: 10.1016/j.jbspin.2017.04.008. [Epub ahead of print]
No abstract available.

PMID:

28499890 Otettu 26.4.2018

[Similar articles](#)

[Use of \(18\)F-fluorodeoxyglucose Positron Emission Tomography to Monitor Disease Activity in Patients With Giant Cell Arteritis on **Tocilizumab**.](#)

Quinn KA, Ahlman MA, Grayson PC.

ACR Open Rheumatol. 2025 Feb;7(2):e11797. doi: 10.1002/acr2.11797.

PMID: 39906912 [Free PMC article.](#) Otettu 14.2.25

Use of 18F-fluorodeoxyglucose positron emission tomography to monitor **tocilizumab** effect on vascular inflammation in giant cell arteritis.

Quinn KA, Dashora H, Novakovich E, Ahlman MA, Grayson PC.

Rheumatology (Oxford). 2020 Dec 28;keaa894. doi: 10.1093/rheumatology/keaa894. Online ahead of print.

PMID: 33369678 Otettu 9.1.21

Impact of dexamethasone and **tocilizumab** on hematological parameters in COVID-19 patients with chronic disease.

Qutob HMH, Saad RA, Bali H, Osailan A, Jaber J, Alzahrani E, Alyami J, Elsayed H, Alserihi R, Shaikhomar OA.

Med Clin (Barc). 2022 Apr 25:S0025-7753(22)00140-3. doi: 10.1016/j.medcli.2022.02.013. Online ahead of print.

PMID: 35659421 **Free PMC article.** Otettu 16.7.22

Tocilizumab for the Treatment of Mevalonate Kinase Deficiency.

Rafiq NK, Lachmann H, Joensen F, Herlin T, Brogan PA.

Case Rep Pediatr. 2018 Aug 26;2018:3514645. doi: 10.1155/2018/3514645. eCollection 2018.

Otettu 2.11.2020

Free PMC Article

[Similar articles](#)

[\[Keratoconjunctivitis associated with atopic dermatitis treated with tocilizumab\].](#)

Raga Jiménez C, Álvarez Martín T, Ferrando Piqueres R, Pitarch Bort G.

Farm Hosp. 2018 Jan 1;42(1):29-30. doi: 10.7399/fh.10885. Spanish. No abstract available.

PMID:

29306313 Otettu t.4.18

[Free Article](#)

[Similar articles](#)

[Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.](#)

Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, Barnes H, Adegunsoye A, Azuma A, Chung L, Gardner GC, Highland KB, Hudson M, Kaner RJ, Kolb M, Scholand MB, Steen V, Thomson CC, Volkmann ER, Wigley FM, Burlile D, Kemper KA, Knight SL, Ghazipura M.

Am J Respir Crit Care Med. 2024 Jan 15;209(2):137-152. doi: 10.1164/rccm.202306-1113ST.

PMID: 37772985 **Free PMC article.** Otettu 7.3.24

[Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.](#)

Rahaghi FF, Hsu VM, Kaner RJ, Mayes MD, Rosas IO, Saggarr R, Steen VD, Strek ME, Bernstein EJ, Bhatt N, Castelino FV, Chung L, Domsic RT, Flaherty KR, Gupta N, Kahaleh B, Martinez FJ, Morrow LE, Moua T, Patel N, Shlobin OA, Southern BD, Volkmann ER, Khanna D.

Respir Res. 2023 Jan 9;24(1):6. doi: 10.1186/s12931-022-02292-3.

PMID: 36624431 **Free PMC article.** Otettu 3.6.23

540.

[An unusual complication of **tocilizumab** therapy: MRI appearances of thenar eminence pyomyositis.](#)

Raine C, Hamdulay SS, Khanna M, Boyer L, Kinderlerer A.

Joint Bone Spine. 2013 Mar;80(2):222. doi: 10.1016/j.jbspin.2012.10.015. Epub 2012 Dec 11.

No abstract available.

PMID:

23237997

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

Tocilizumab Use in Children with Cytokine Release **Syndrome**.

Raj R, Uppuluri R, Venkateswaran VS.

Indian Pediatr. 2021 Feb 15;58(2):186-187.

PMID: 33632957 Otettu 6.8.21

.

[Antagonizing IL-6 in ankylosing spondylitis: a short review.](#)

Rajalingham S, Das S.

Inflamm Allergy Drug Targets. 2012 Aug 1;11(4):262-5. Review.

PMID:

22452603

[PubMed - indexed for MEDLINE] Ei ole M

[Related citations](#)

Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review.

Raleigh MF, Stoddard J, Darrow HJ.

Am Fam Physician. 2022 Oct;106(4):420-426.

PMID: 36260899 Otettu 3.6.23

A phase II trial protocol of **Tocilizumab** in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial).

Ramanan AV, Dick AD, Jones AP, Guly C, Hardwick B, Hickey H, Lee R, McKay A, Beresford MW; APTITUDE Trial Management Group.

BMC Rheumatol. 2018 Feb 27;2:4. doi: 10.1186/s41927-018-0010-2. eCollection 2018.

PMID: 30886955 [Free PMC article.](#) Otettu 2.11.20

Tocilizumab in patients with anti-TNF refractory juvenile idiopathic **arthritis**-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial.

Ramanan AV, Dick AD, Guly C, McKay A, Jones AP, Hardwick B, Lee RWJ, Smyth M, Jaki T, Beresford MW; APTITUDE Trial Management Group.

Lancet Rheumatol. 2020 Feb 7;2(3):e135-e141. doi: 10.1016/S2665-9913(20)30008-4.

eCollection 2020 Mar.

PMID: 32280950 [Free PMC article.](#) Otettu 2.11.20

[Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.](#)

Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewé R.

Ann Rheum Dis. 2014 Mar;73(3):529-35. doi: 10.1136/annrheumdis-2013-204575. Epub 2014 Jan 8. Review.

PMID:

24401994

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

[**Tocilizumab in Refractory Autoimmune Encephalitis: A Series of Pediatric Cases.**](#)

Randell RL, Adams AV, Van Mater H.

Pediatr Neurol. 2018 Aug 3. pii: S0887-8994(18)30366-7. doi: 10.1016/j.pediatrneurol.2018.07.016. [Epub ahead of print]

PMID:

30177347 Otettu 25.9.18

[Similar articles](#)

[An evaluation of risk factors for major adverse cardiovascular events during **tocilizumab** therapy.](#)

Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, Sattar N, Lee JS. Arthritis Rheumatol. 2015 Feb;67(2):372-80. doi: 10.1002/art.38920.

PMID:

25332171

[PubMed - in process] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

[The Efficacy and Safety of Abatacept, Adalimumab, Etanercept And **Tocilizumab** are Comparable In Polyarticular Juvenile Idiopathic Arthritis.](#)

Rathi H, Pennington B, Amadi A, Lister S, Nanuwa K.

Value Health. 2015 Nov;18(7):A636. doi: 10.1016/j.jval.2015.09.2258. Epub 2015 Oct 20. No abstract available.

PMID: ei oteta

26533567

[Free Article](#)

[Similar articles](#)

[Tropheryma Whipplei infection mimicking giant cell arteritis flare in a patient treated with interleukin-6 receptor blocker **tocilizumab**.](#)

Razanamahery J, Humbert S, Gil H, Bouiller K, Magy-Bertrand N.

Clin Exp Rheumatol. 2020 Mar-Apr;38 Suppl 124(2):245-246. Epub 2020 Apr 10.

PMID: 32301419 Otettu 9.1.21

[Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study.](#)

Rebić N, Sayre EC, Zusman EZ, Amiri N, Baldwin C, De Vera MA.

Rheumatology (Oxford). 2020 Jul 1;59(7):1514-1521. doi: 10.1093/rheumatology/kez478.

PMID: 31628479 Otettu 9.1.21

[Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade.](#)

Rech J, Ronneberger M, Englbrecht M, Finzel S, Katzenbeisser J, Manger K, Manger B, Schett G.

Ann Rheum Dis. 2011 Feb;70(2):390-2. doi: 10.1136/ard.2010.129403. Epub 2010 Jul 22. No abstract available.

PMID:

20650873

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

484.

[Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease.](#)

Redondo-Pachón MD, Enríquez R, Sirvent AE, Andrada E, Noguera-Pons R, Millán I, Amorós F. Ren Fail. 2013;35(4):547-50. doi: 10.3109/0886022X.2013.773913. Epub 2013 Mar 11.

PMID:

23472940

[PubMed - indexed for MEDLINE] Ei aukea M

[Related citations](#)

[Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.](#)

Régent A, Redeker S, Deroux A, Kieffer P, Ly KH, Dougados M, Liozon E, Larroche C, Guillevin L, Bouillet L, Espitia O, Costedoat-Chalumeau N, Soubrier M, Brihaye B, Lifermann F, Lefevre G, Puéchal X, Mouthon L, Toussirot E; French Vasculitis Group, the Groupe Francais pour l'Etude de l'Artérite à Cellules Géantes, and the Club Rhumatismes et Inflammation.

J Rheumatol. 2016 Aug;43(8):1547-52. doi: 10.3899/jrheum.151252. Epub 2016 May 15.

PMID: Otettu 26.4.2018

27182063

[Similar articles](#)

Treatment of Giant Cell Arteritis (GCA).

Régent A, Mouthon L.

J Clin Med. 2022 Mar 24;11(7):1799. doi: 10.3390/jcm11071799.

PMID: 35407411 [Free PMC article](#). Otettu 17.7.22

Long-term treatment with **tocilizumab** in giant cell arteritis: efficacy and safety in a monocentric cohort of patients.

Regola F, Cerudelli E, Bosio G, Andreoli L, Tincani A, Franceschini F, Toniati P.

Rheumatol Adv Pract. 2020 May 15;4(2):rkaa017. doi: 10.1093/rap/rkaa017. eCollection 2020.

PMID: 32685912 [Free PMC article](#). Otettu 9.1.21

Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of **tocilizumab** in giant cell arteritis.

Reichenbach S, Adler S, Bonel H, Cullmann JL, Kuchen S, Bütikofer L, Seitz M, Villiger PM.

Rheumatology (Oxford). 2018 Feb 23. doi: 10.1093/rheumatology/key015. [Epub ahead of print]
PMID:

29529280 Otettu 26.4.2018

[Similar articles](#)

[Treatment of Systemic Juvenile Idiopathic Arthritis with **Tocilizumab** - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment.](#)

Reiff A.

Biol Ther. 2012 Feb 1;2:1. eCollection 2012. Review.

PMID:

24392296 [Kokotekstinä](#) Ei oteta

[PubMed]

[Free PMC Article](#)

[Related citations](#)

Treatment of refractory adult onset Still's disease with **tocilizumab**-a single centre experience and literature review.

Reihl Crnogaj M, Čubelić D, Babić A, Mayer M, Anić B.

Rheumatol Int. 2020 Aug;40(8):1317-1325. doi: 10.1007/s00296-020-04622-4. Epub 2020 Jun 6.

PMID: 32506202 Review. Otettu 9.1.21

Tuberculosis sepsis after **tocilizumab** treatment.

Reisinger AC, Hermann J, Vagena FR, Hackl G, Eller P.

Clin Microbiol Infect. 2020 Nov;26(11):1493-1494. doi: 10.1016/j.cmi.2020.05.030. Epub 2020 Jun 5.

PMID: 32512231 [Free PMC article.](#) Otettu 9.1.21

12.

[Interpreting the multi-biomarker disease activity score in the context of **tocilizumab** treatment for patients with rheumatoid arthritis.](#)

Reiss WG, Devenport JN, Low JM, Wu G, Sasso EH.

Rheumatol Int. 2015 May 31. [Epub ahead of print]

PMID:

26026604 Otettu 29.6.15

[Similar articles](#)

[Risk of Diverticulitis and Gastrointestinal Perforation in Rheumatoid Arthritis Treated with **Tocilizumab** Compared to Rituximab or Abatacept.](#)

Rempenault C, Lukas C, Combe B, Herrero A, Pane I, Schaefferbeke T, Wendling D, Pham T, Gottenberg JE, Mariette X, Morel J; French Society of Rheumatology and the investigators participating in AIR-PR, ORA, and REGATE registries.

Rheumatology (Oxford). 2021 May 16;keab438. doi: 10.1093/rheumatology/keab438. Online ahead of print.

PMID: 33993216 Otta M

[A case of CLIPPERS syndrome responsive to **tocilizumab**.](#)

Rempe T, Becktepe JS, Metz I, Brück W, Stürner KH, Deuschl G, Berg D, Baron R, Zeuner R, Leypoldt F.

Neurol Neuroimmunol Neuroinflamm. 2019 Feb 1;6(3):e545. doi:

10.1212/NXI.0000000000000545. eCollection 2019 May.

PMID: 30882019 [Free PMC article](#). Otettu 9.1.21

Effects of interleukin-6 receptor blockade on allergen-induced airway responses in mild asthmatics.

Revez JA, Bain LM, Watson RM, Towers M, Collins T, Killian KJ, O'Byrne PM, Gauvreau GM, Upham JW, Ferreira MA.

Clin Transl Immunology. 2019 Jun 14;8(6):e1044. doi: 10.1002/cti2.1044. eCollection 2019.

PMID: 31223480 [Free PMC article](#). Otettu 9.1.21

[Correction to: Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study.](#)

[No authors listed]

Rheumatology (Oxford). 2024 Mar 27;keae184. doi: 10.1093/rheumatology/keae184. Online ahead of print.

PMID: 38545738 Otettu 17.4.24

Anti-Rheumatic potential of biological DMARDS and protgonistic role of bio-markers in early detection and management of rheumatoid arthritis.

Riaz M, Rasool G, Yousaf R, Fatima H, Munir N, Ejaz H.

Innate Immun. 2025 Jan-Dec;31:17534259251324820. doi: 10.1177/17534259251324820.
Epub 2025 Mar 16.
PMID: 40091354 [Free PMC article](#). Review. Otettu 30.3.25

Changes in Iron Metabolism Induced by Anti-Interleukin-6 Receptor Monoclonal Antibody are Associated with an Increased Risk of Infection.
Ribeiro R, Batista F, Seguro Paula F, Delgado Alves J.
Pharmaceuticals (Basel). 2019 Jun 28;12(3):100. doi: 10.3390/ph12030100.
PMID: 31261772 [Free PMC article](#). Otettu 2.11.20

[Report of two cases of tocilizumab induced recurrent meningitis or meningoencephalitis.](#)

Richebé P, Bailly F, Mariani LL, Pena PS, Pedespan JM, Fautrel B.

Joint Bone Spine. 2018 Jan 31. pii: S1297-319X(18)30004-6. doi: 10.1016/j.jbspin.2018.01.002. [Epub ahead of print]
No abstract available.

PMID:

29366968 Otettu 4.5.18

[Similar articles](#)

Efficacy of **tocilizumab** in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial.

Richette P, Latourte A, Sellam J, Wendling D, Piperno M, Goupille P, Pers YM, Eymard F, Ottaviani S, Ornetti P, Flipo RM, Fautrel B, Peyr O, Bertola JP, Vicaut E, Chevalier X.

Ann Rheum Dis. 2020 Oct 14:annrheumdis-2020-218547. doi:

10.1136/annrheumdis-2020-218547. Online ahead of print.

PMID: 33055078 Otettu 9.1.21

[Tocilizumab treatment decreases circulating myeloid dendritic cells and monocytes. 2 components of the myeloid lineage.](#)

Richez C, Barnetche T, Khoryati L, Duffau P, Kostine M, Contin-Bordes C, Blanco P, Schaeffer T.

J Rheumatol. 2012 Jun;39(6):1192-7. doi: 10.3899/jrheum.111439. Epub 2012 Apr 1.

PMID:

22467922

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

[Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases.](#)

Richi P, Yuste J, Navío T, González-Hombrado L, Salido M, Thuissard-Vasallo I, Jiménez-Díaz A, Llorente J, Cebrián L, Lojo L, Steiner M, Cobo T, Martín MD, García-Castro M, Castro P, Muñoz-Fernández S.

Vaccines (Basel). 2021 Feb 28;9(3):203. doi: 10.3390/vaccines9030203.

PMID: 33671007 [Free PMC article.](#) Otettu 6.8.21

Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study.

Richi P, Alonso O, Martín MD, González-Hombrado L, Navío T, Salido M, Llorente J, Andreu-Vázquez C, García-Fernández C, Jiménez-Díaz A, Lojo L, Cebrián L, Thuissard-Vasallo I, Martínez de Aramayona MJ, Cobo T, García-Castro M, Castro P, Fernández-Castro M, Illera Ó, Steiner M, Muñoz-Fernández S.

Clin Rheumatol. 2020 Sep;39(9):2751-2756. doi: 10.1007/s10067-020-05042-2. Epub 2020 Apr 4.

PMID: 32248433 Otettu 9.1.21

[Does **tocilizumab** eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies.](#)

Ricordi C, Marvisi C, Macchioni P, Boiardi L, Cavazza A, Croci S, Bonacini M, Malchiodi G, Durmo R, Versari A, Mancuso P, Giorgi Rossi P, Muratore F, Salvarani C.

RMD Open. 2024 Dec 31;10(4):e005132. doi: 10.1136/rmdopen-2024-005132.

PMID: 39740930 **Free PMC article.** Otettu 14.2.25

Off-label use of **tocilizumab** in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series.

Rigal J, Pugnet G, Ciron J, Lépine Z, Biotti D.

Mult Scler Relat Disord. 2020 Nov;46:102483. doi: 10.1016/j.msard.2020.102483. Epub 2020 Sep 3.

PMID: 32942119 Otta M

[Giant cell arteritis: An updated review of an old disease.](#)

Rinden T, Miller E, Nasr R.

Cleve Clin J Med. 2019 Jul;86(7):465-472. doi: 10.3949/ccjm.86a.18103.

PMID: 31291180 [Free article](#). Otettu 9.1.21

[Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.](#)

Ringelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, Hayward-Könnecke H, Schippling S, Rommer PS, Kornek B, Zrzavy T, Biotti D, Ciron J, Audoin B, Berthele A, Giglhuber K, Zephir H, Kümpfel T, Berger R, Röther J, Häußler V, Stellmann JP, Whittam D, Jacob A, Kraemer M, Gueguen A, Deschamps R, Bayas A, Hümmert MW, Trebst C, Haarmann A, Jarius S, Wildemann B, Grothe M, Siebert N, Ruprecht K, Paul F, Collongues N, Marignier R, Levy M, Karenfort M, Deppe M, Albrecht P, Hellwig K, Gold R, Hartung HP, Meuth SG, Kleiter I, Aktas O; Neuromyelitis Optica Study Group (NEMOS).

Neurol Neuroimmunol Neuroinflamm. 2021 Nov 16;9(1):e1100. doi:

10.1212/NXI.0000000000001100. Print 2022 Jan.

PMID: 34785575 [Free PMC article](#). Otettu 16.7.22

[Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.](#)

Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I.

JAMA Neurol. 2015 May 18. doi: 10.1001/jamaneurol.2015.0533. [Epub ahead of print]

PMID:

25985228 Otettu 2.6.15

[Related citations](#)

[Dramatic Response to **Tocilizumab** Before Emergency Surgery in Severe Active Takayasu Disease.](#)

Risse J, Mandry D, Settembre N, Vigouroux C, Claudin M, Tsintzila G, Huttin O, Malikov S, Zuily S, Wahl D.

Circ Cardiovasc Imaging. 2016 Jul;9(7). pii: e004819. doi: 10.1161/CIRCIMAGING.116.004819. No abstract available.

PMID: Otettu 5.4.18

27406844

[Free Article](#)

[Similar articles](#)

[Rituximab versus **tocilizumab** in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.](#)

Rivellese F, Surace AEA, Goldmann K, Sciacca E, Çubuk C, Giorli G, John CR, Nerviani A, Fossati-Jimack L, Thorborn G, Ahmed M, Prediletto E, Church SE, Hudson BM, Warren SE, McKeigue PM, Humby F, Bombardieri M, Barnes MR, Lewis MJ, Pitzalis C; R4RA collaborative group.

Nat Med. 2022 Jun;28(6):1256-1268. doi: 10.1038/s41591-022-01789-0. Epub 2022 May 19.

PMID: 35589854 [Free PMC article](#). Clinical Trial. Otettu 16.7.22

[Stratification of biological therapies by pathobiology in biologic-naïve patients with rheumatoid arthritis \(STRAP and STRAP-EU\): two parallel, open-label, biopsy-driven, randomised trials.](#)

Rivellese F, Nerviani A, Giorli G, Warren L, Jaworska E, Bombardieri M, Lewis MJ, Humby F, Pratt AG, Filer A, Gendi N, Cauli A, Choy E, McInnes I, Durez P, Edwards CJ, Buch MH, Gremese E, Taylor PC, Ng N, Cañete JD, Raizada S, McKay ND, Jadon D, Sainaghi PP, Stratton R, Ehrenstein MR, Ho P, Pereira JP, Dasgupta B, Gorman C, Galloway J, Chinoy H, van der Heijde D, Sasieni P, Barton A, Pitzalis C; STRAP collaborative group.

Lancet Rheumatol. 2023 Nov;5(11):e648-e659. doi: 10.1016/S2665-9913(23)00241-2.

PMID: 38251532 [Free article](#). Clinical Trial. Otettu 7.3.24

[Early anti-inflammatory therapy in acute myocardial infarction: A network meta-analysis of timing-dependent effects in 23 randomized trials and 28,220 patients.](#)

Rivero-Santana B, Saldaña-García J, Jurado-Román A, Cantolla-Pablo P, Gil-Fernández M, López-Sendón J, Tardif JC, Moreno R, Fernández-Velasco M.

Atherosclerosis. 2025 Jul 12;408:120443. doi: 10.1016/j.atherosclerosis.2025.120443. Online ahead of print.

PMID: 40674948 Ota

[Update on the management of giant cell arteritis.](#)

Roberts J, Clifford A.

Ther Adv Chronic Dis. 2017 Apr;8(4-5):69-79. doi: 10.1177/2040622317700089. Epub 2017 Mar 28. Review.

PMID:

28491267 Otettu 5.4.18

[Free PMC Article](#)

[Similar articles](#)

[Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis.](#)

Robertson J, Porter D, Sattar N, Packard CJ, Caslake M, McInnes I, McCarey D.

Ann Rheum Dis. 2017 Nov;76(11):1949-1952. doi: 10.1136/annrheumdis-2017-211708. Epub 2017 Sep 15.

PMID:

28916714 Otettu 2.5.2018

[Similar articles](#)

[Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia.](#)

Robinson L, Hamden M, Griggs K, Simon S, Hill C, Limaye V, Proudman S.

Intern Med J. 2024 Jul;54(7):1228-1232. doi: 10.1111/imj.16419. Epub 2024 Jul 2.

PMID: 38953308 Otta M

169.

[Hypersensitivity reactions to **tocilizumab**: role of skin tests in diagnosis.](#)

Rocchi V, Puxeddu I, Cataldo G, Del Corso I, Tavoni A, Bazzichi L, Bombardieri S, Migliorini P. Rheumatology (Oxford). 2014 Aug;53(8):1527-9. doi: 10.1093/rheumatology/keu181. Epub 2014 Jun 4. No abstract available.

PMID:

24899663

[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study.

Roddy J, Wells D, Schenck K, Santosh S, Santosh S.

Crit Care Explor. 2022 May 11;4(5):e0702. doi: 10.1097/CCE.0000000000000702. eCollection 2022 May.

PMID: 35783551 [Free PMC article.](#) Otettu 16.7.22

[Systemic sclerosis-associated severe gastric antral vascular ectasia treated with tocilizumab: A case report and review of the literature.](#)

Rodolfi S, Denton CP, Ong VH.

J Scleroderma Relat Disord. 2025 Jan 8;23971983241309570. doi: 10.1177/23971983241309570. Online ahead of print.

PMID: 39802335 [Free PMC article.](#) Otettu 14.2.25

[AA amyloidosis revealing mevalonate kinase deficiency: A report of 20 cases including two new French cases and a comprehensive review of literature.](#)

Rodrigues F, Philit JB, Giurgea I, Anglicheau D, Roux JJ, Hoyeau N, Grateau G, Cuisset L, Georgin-Lavialle S.

Semin Arthritis Rheum. 2020 Mar 19:S0049-0172(20)30078-0. doi: 10.1016/j.semarthrit.2020.03.005. Online ahead of print.
PMID: 32252977 Otettu 2.11.20

Treating Adult-Onset Still Disease With **Tocilizumab: A Case-Based Review.**

Rodrigues J, Santos-Faria D, Silva J, Azevedo S, Guimarães F, Esperança Almeida D, Teixeira F, Peixoto D, Alcino S, Afonso C, Tavares-Costa J.
J Clin Rheumatol. 2020 Apr 2. doi: 10.1097/RHU.0000000000001381. Online ahead of print.
PMID: 32251045 No abstract available. Otta M

Disease Activity Indices in Rheumatoid Arthritis: Comparative Performance to Detect Changes in Function, IL-6 Levels, and Radiographic Progression.

Rodriguez-García SC, Montes N, Ivorra-Cortes J, Triguero-Martinez A, Rodriguez-Rodriguez L, Castrejón I, Carmona L, González-Álvaro I.
Front Med (Lausanne). 2021 May 31;8:669688. doi: 10.3389/fmed.2021.669688. eCollection 2021.
PMID: 34136506 **Free PMC article.** Otettu 6.8.21

Role of interleukin-6 in stress, sleep, and fatigue.

Rohleder N, Aringer M, Boentert M.
Ann N Y Acad Sci. 2012 Jul;1261:88-96. doi: 10.1111/j.1749-6632.2012.06634.x. Review.
PMID:
22823398
[PubMed - indexed for MEDLINE] Otettu 2.6.15

[Related citations](#)

930.

[\[Tocilizumab. What comes after TNF-blockers in clinical routine?\]](#).

Roll P, Rubbert-Roth A, Tony HP.

Z Rheumatol. 2010 Sep;69(7):608-17. doi: 10.1007/s00393-009-0529-0. German.

PMID:

20703490

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment.](#)

Roll P, Muhammad K, Schumann M, Kleinert S, Einsele H, Dörner T, Tony HP.

Arthritis Rheum. 2011 May;63(5):1255-64. doi: 10.1002/art.30242.

PMID:

21305508

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

[Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.](#)

Romano C, Del Mastro A, Sellitto A, Solaro E, Esposito S, Cuomo G.

Clin Rheumatol. 2018 Jan 23. doi: 10.1007/s10067-018-3992-7. [Epub ahead of print]

PMID:

29362962 Otettu 7.5.2018

[Similar articles](#)

[Hepatitis B vaccination associated with low response in patients with rheumatic diseases treated with biologics.](#)

Romão VC, Ávila-Ribeiro P, Gonçalves MJ, Cruz-Machado R, Guerreiro AB, Teixeira V, Valido A, Silva-Dinis J, Vieira-Sousa E, Saavedra MJ, Sacadura-Leite E, Marinho RT, Fonseca JE.

RMD Open. 2023 Dec 6;9(4):e003597. doi: 10.1136/rmdopen-2023-003597.

PMID: 38056920 [Free PMC article.](#) Otettu 7.3.24

[Comparative Effectiveness of **Tocilizumab** and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt.](#)

C Romão V, Santos MJ, Polido-Pereira J, Duarte C, Nero P, Miguel C, Costa JA, Bernardes M, Pimentel-Santos FM, Barcelos F, Costa L, Melo Gomes JA, Pereira da Silva JA, Branco JC, Canas da Silva J, Pereira da Silva JA, Fonseca JE, Canhão H.

Biomed Res Int. 2015;2015:279890. Epub 2015 Apr 27. Otettu 24.7.15

PMID:

26000286

[Free Article](#)

[Related citations](#)

[**Tocilizumab** Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.](#)

Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, Huang S, Khanna D; focuSSced Investigators.

Arthritis Rheumatol. 2021 Jul;73(7):1301-1310. doi: 10.1002/art.41668. Epub 2021 May 25.

PMID: 33538094 Otettu 6.8.21

[Treatment for systemic sclerosis-associated interstitial lung disease.](#)

Roofeh D, Lescoat A, Khanna D.

Curr Opin Rheumatol. 2021 May 1;33(3):240-248. doi: 10.1097/BOR.0000000000000795.

PMID: 33741803 Otettu 6.8.21

[Two flares of Still's disease after two doses of the ChAdOx1 vaccine.](#)

Roongta R, Mondal S, Halder S, Kumar MS, Ghosh A.

Clin Rheumatol. 2022 Mar 6:1-6. doi: 10.1007/s10067-022-06124-z. Online ahead of print.

PMID: 35249157 [Free PMC article](#). Review. Otettu 16.7.22

[Necrotizing fasciitis in a patient receiving **tocilizumab** for rheumatoid arthritis - Case report.](#)

Rosa-Gonçalves D, Bernardes M, Costa L.

Reumatol Clin. 2016 Dec 29. pii: S1699-258X(16)30152-8. doi: 10.1016/j.reuma.2016.10.008. [Epub ahead of print] English, Spanish.

PMID:

28041910 Otettu 5.4.18

[Free Article](#)

[Similar articles](#)

Posterior reversible encephalopathy syndrome during treatment with **tocilizumab** in juvenile idiopathic **arthritis**.

Rosa Júnior M, Borges ÉI, Fonseca APA, Fiorot JL, Balarini L, Valim V.

Arq Neuropsiquiatr. 2018 Oct;76(10):720-721. doi: 10.1590/0004-282X20180093. Otettu 2.11.20

Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).

Rosas IO, Bräu N, Waters M, Go RC, Malhotra A, Hunter BD, Bhagani S, Skiest D, Savic S, Douglas IS, Garcia-Diaz J, Aziz MS, Cooper N, Youngstein T, Sorbo LD, Zerda DJ, Ustianowski A, Gracian AC, Blyth KG, Carratalà J, François B, Benfield T, Haslem D, Bonfanti P, van der Leest CH, Rohatgi N, Wiese L, Luyt CE, Bauer RN, Cai F, Lee IT, Matharu B, Metcalf L, Wildum S, Graham E, Tsai L, Bao M.

EClinicalMedicine. 2022 May;47:101409. doi: 10.1016/j.eclinm.2022.101409. Epub 2022 Apr 21. PMID: 35475258 **Free PMC article.** Otettu 16.7.22

293.

[The role of IL-6 in host defence against infections: immunobiology and clinical implications.](#)

Rose-John S, Winthrop K, Calabrese L.

Nat Rev Rheumatol. 2017 Jul;13(7):399-409. doi: 10.1038/nrrheum.2017.83. Epub 2017 Jun 15. Review.

PMID:

28615731 Otettu 2.5.2018

[Similar articles](#)

Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis.

Rosenberg V, Chodick G, Xue Z, Faccin F, Amital H.

Adv Ther. 2023 Aug 11. doi: 10.1007/s12325-023-02607-w. Online ahead of print.

PMID: 37566157 Otettu 30.8.23

469.

[Biologic therapy for autoimmune diseases: an update.](#)

Rosman Z, Shoenfeld Y, Zandman-Goddard G.

BMC Med. 2013 Apr 4;11:88. doi: 10.1186/1741-7015-11-88. Review.

PMID:

23557513

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

An agent-to-agent real life comparison study of **tocilizumab** versus abatacept in giant cell arteritis.

Rossi D, Cecchi I, Sciascia S, Naretto C, Alpa M, Roccatello D.

Clin Exp Rheumatol. 2021 Mar-Apr;39 Suppl 129(2):125-128. Epub 2021 Feb 23.

PMID: 33635228 Otettu 6.8.21

38.

[Interleukin-6 as a Therapeutic Target.](#)

Rossi JF, Lu ZY, Jourdan M, Klein B.

Clin Cancer Res. 2015 Mar 15;21(6):1248-1257. Epub 2015 Jan 14. Review.

PMID:

25589616

[PubMed - as supplied by publisher] Otettu 3.6.15

[Related citations](#)

[Rheumatoid arthritis: Biological therapy other than anti-TNF.](#)

Rossi D, Modena V, Sciascia S, Roccatello D.

Int Immunopharmacol. 2015 Mar 31. pii: S1567-5769(15)00121-6. doi:

10.1016/j.intimp.2015.03.019. [Epub ahead of print] Review.

PMID:

25840282 Otettu 3.6.15

[Related citations](#)

[Low-dose **tocilizumab** for relapsing giant cell arteritis in the elderly, fragile patient: Beyond the GiACTA trial.](#)

Rossi GM, Mannoni A, Di Scala G, Silvestri E, Cojan RD, Vannozzi L, Bettiol A, Vaglio A, Emmi G.

Autoimmun Rev. 2018 Dec;17(12):1265-1267. doi: 10.1016/j.autrev.2018.07.004. Epub 2018 Oct 12.

PMID: 30316991 Otta M

[Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options.](#)

Rosso M, Saxena S, Chitnis T.

Expert Rev Neurother. 2020 May;20(5):509-516. doi: 10.1080/14737175.2020.1757434. Epub 2020 Apr 26.
PMID: 32306778 Otta M

Tocilizumab in the treatment of systemic-onset juvenile idiopathic **arthritis** - single-centre experience.

Roszkiewicz J, Orczyk K, Smolewska E.

Reumatologia. 2018;56(5):279-284. doi: 10.5114/reum.2018.79497. Epub 2018 Oct 31.

PMID: 30505008 **Free PMC article.** Otettu 2.11.20

[Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.](#)

Roubille C, Haraoui B.

Semin Arthritis Rheum. 2014 Apr;43(5):613-26. doi: 10.1016/j.semarthrit.2013.09.005. Epub 2013 Oct 5. Review.

PMID:

24231065

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Ophthalmic herpes zoster infection in patients with rheumatoid arthritis who were treated with tocilizumab.](#)

Roux C, Breuil V, Albert C, Allam V, Grisot C, Chami H, Dasilva V, Euller-Ziegler L.

J Rheumatol. 2011 Feb;38(2):399. doi: 10.3899/jrheum.100737. No abstract available.

PMID:

21285184

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Assessing the safety of biologic agents in patients with rheumatoid arthritis.](#)

Rubbert-Roth A.

Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v38-47. doi: 10.1093/rheumatology/kes114.

Review.

PMID:

22718926

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

[Malignancy rates in patients with rheumatoid arthritis treated with **tocilizumab**.](#)

Rubbert-Roth A, Sebba A, Brockwell L, Kelman A, Porter-Brown B, Pulley J, Napalkov P, van Vollenhoven RF.

RMD Open. 2016 May 10;2(1):e000213. doi: 10.1136/rmdopen-2015-000213. eCollection 2016.

PMID: Otettu 5.4.18

27252893

[Free PMC Article](#)

[Similar articles](#)

[A Review of Recent Advances Using **Tocilizumab** in the Treatment of Rheumatic Diseases.](#)

Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E.

Rheumatol Ther. 2018 Mar 3. doi: 10.1007/s40744-018-0102-x. [Epub ahead of print] Review.

PMID:

29502236 Otettu 5.4.18

[Free Article](#)

[Similar articles](#)

Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of **tocilizumab** for rheumatoid **arthritis**.

Rubbert-Roth A, Aletaha D, Devenport J, Sidiropoulos PN, Luder Y, Edwardes MD, Jacobs JWG. Rheumatology (Oxford). 2020 Aug 26;keaa259. doi: 10.1093/rheumatology/keaa259. Online ahead of print.

PMID: 32844216 Otettu 2.11.20

539.

[Overview of safety of non-biologic and biologic DMARDs.](#)

Ruderman EM.

Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi37-43. doi: 10.1093/rheumatology/kes283. Review.

PMID:

23221586

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

310.

[The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis.](#)

Ruderman EM.

Bull Hosp Jt Dis (2013). 2013;71 Suppl 1:S29-32. Review.

PMID:

24219038

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

792.

[\[Tocilizumab in rheumatoid arthritis\].](#)

Rueda Gotor J, Blanco Alonso R.

Reumatol Clin. 2011 Mar;6S3:S29-32. doi: 10.1016/j.reuma.2011.01.001. Epub 2011 Mar 23.

Spanish.

PMID:

21794769

[PubMed - in process] Espnaja. Ei oteta

[Free Article](#)

[Related citations](#)

7.

[Successful effect of tocilizumab in anti-TNF- \$\alpha\$ -induced palmoplantar pustulosis in rheumatoid arthritis.](#)

Rueda-Gotor J, González-Gay MA, Blanco Alonso R, Gonzalez-Vela C, Lopez-Obregon C, González-López MA.

Joint Bone Spine. 2012 Oct;79(5):510-3. doi: 10.1016/j.jbspin.2012.06.010. Epub 2012 Aug 2.

PMID:

22857979

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Temporal arteritis and vasculitic myopathy in polyarteritis nodosa.](#)

Ruffer N, Haase I, Xiong T, Prinz F, Koehler D, Kötter I, Krusche M.
J Neurol. 2025 Jul 9;272(8):496. doi: 10.1007/s00415-025-13199-6.
PMID: 40632242 [Free PMC article.](#) Ota

[The role of **tocilizumab** in the treatment of inflammatory diseases of the eye and orbit:
A useful alternative.](#)

Ruiz-Medrano J, Díaz-Valle D, Cuiña R, Gegúndez JA, Chhablani J, Majumder PD,
Gutierrez-Bonet R.
J Fr Ophtalmol. 2018 Sep 11. pii: S0181-5512(18)30282-1. doi: 10.1016/j.jfo.2018.02.006. [Epub ahead of print]
Review.
PMID:

30217605 ei ole M

[Similar articles](#)

[Subcutaneous dosing regimens of **tocilizumab** in children with systemic or polyarticular juvenile idiopathic arthritis.](#)

Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Pérez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, De Benedetti F; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Rheumatology (Oxford). 2021 Jan 28;keab047. doi: 10.1093/rheumatology/keab047. Online ahead of print.
PMID: 33506875 Otettu 6.8.21

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.

Russell DJ, Wagner LH, Seiff SR.

Am J Ophthalmol Case Rep. 2017 Jul 8;7:146-148. doi: 10.1016/j.ajoc.2017.07.001. eCollection 2017 Sep.

PMID:

29260102 Otettu 5.4.18

Free PMC Article

[Similar articles](#)

**Tocilizumab-Associated Small Bowel Perforation in a Young Patient With Rheumatoid Arthritis:
A Lesson to Remember During COVID-19 Pandemic.**

Saad E, Awadelkarim A, Agab M, Babkir A.

J Med Cases. 2022 Mar;13(3):135-139. doi: 10.14740/jmc3902. Epub 2022 Mar 5.

PMID: 35356392 **Free PMC article.** Otettu 17.7.22

**Treatment of rheumatoid arthritis-associated interstitial lung disease: An appraisal of the 2023
ACR/CHEST guideline.**

Saavedra AA, Mueller KT, Kowalski EN, Qian G, Bade KJ, Vanni KM, McDermott GC, Sparks JA.

Curr Treatm Opt Rheumatol. 2024 Dec;10(4):43-60. doi: 10.1007/s40674-024-00217-3. Epub 2024 Sep 16.

PMID: 39822854 Otta M

Multiple lesions of cutaneous focal mucinosis in a patient receiving treatment with **tocilizumab**:
Coincidence or causality?

Sabater-Abad J, Matellanes-Palacios M, Bou-Boluda L, Navarro-Conde P, Sabater-Marco V,
Quecedo-Estébanez E.

Australas J Dermatol. 2020 Nov;61(4):e456-e458. doi: 10.1111/ajd.13360. Epub 2020 Jun 23.
PMID: 32578206 Otta M

.
[**Tocilizumab** in refractory adult-onset Still's disease with aseptic meningitis--efficacy of
interleukin-6 blockade and review of the literature.](#)

Sabnis GR, Gokhale YA, Kulkarni UP.

Semin Arthritis Rheum. 2011 Feb;40(4):365-8. doi: 10.1016/j.semarthrit.2010.05.003. Review.

PMID:

20621335

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

Randomized clinical trials on the efficacy and safety of **tocilizumab** in subjects with rheumatoid
arthritis: a systematic review.

Sadeq A, Elnour AA, Ramadan A, Yousif El Khidir I, Don J, Al Amoodi A, Al Mazrouei N, A Baraka M, Hamad Farah F, Alkaabi M.

Curr Rev Clin Exp Pharmacol. 2022 Feb 2. doi: 10.2174/2772432817666220202115623. Online ahead of print.

PMID: 35114930 Otta M

Posterior segment inflammatory outcomes assessed using fluorescein angiography in the STOP-UVEITIS study.

Sadiq MA, Hassan M, Afridi R, Halim MS, Do DV, Sepah YJ, Nguyen QD; STOP-UVEITIS Investigators.

Int J Retina Vitreous. 2020 Oct 6;6:47. doi: 10.1186/s40942-020-00245-w. eCollection 2020.

PMID: 33042579 [Free PMC article.](#) Otettu 9.1.21

Should **Tocilizumab** Be Used Routinely in New Patients With a Diagnosis of Giant Cell Arteritis?

Sadun A, Gordon L.

J Neuroophthalmol. 2020 Mar;40(1):117-121. doi: 10.1097/WNO.0000000000000869.

PMID: 31834197 Otta M

Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid **arthritis** clinical trials of **tocilizumab** or adalimumab or methotrexate monotherapy.

Safy-Khan M, Jacobs JWJ, de Hair MJH, Welsing PMJ, Edwardes MD, Teitsma XM, Luder Y, Devenport J, van Laar JM, Pethoe-Schramm A, Bijlsma JWJ.

Ann Rheum Dis. 2020 Apr;79(4):460-463. doi: 10.1136/annrheumdis-2019-216537. Epub 2020 Feb 7.

PMID: 32033935 Otettu 2.11.20

[The efficacy and safety of reinstitution of **tocilizumab** in patients with relapsed active rheumatoid arthritis after long-term withdrawal of **tocilizumab**: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.](#)

Sagawa A.

Mod Rheumatol. 2011 Aug;21(4):352-8. doi: 10.1007/s10165-011-0419-6. Epub 2011 Feb 24.

PMID:

21347804

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

Select item 21346578852.

[IL-6 as a druggable target in psoriasis: focus on pustular variants.](#)

Saggini A, Chimenti S, Chiricozzi A.

J Immunol Res. 2014;2014:964069. doi: 10.1155/2014/964069. Epub 2014 Jul 13.

PMID:

25126586

[PubMed - in process] Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

Tocilizumab for relapsing and remitting giant cell arteritis: a case series.

Saha P, Srikantharajah D, Kaul A, Sofat N.

J Med Case Rep. 2022 Oct 27;16(1):389. doi: 10.1186/s13256-022-03625-y.

PMID: 36289554 [Free PMC article.](#) Otettu 3.6.23

[A Spectacular Effect of **Tocilizumab** in Takayasu Arteritis.](#)

Saïd F, Naceur I, Ben Achour T, Jridi M, Smiti M.

Eur J Case Rep Intern Med. 2024 Nov 7;11(12):004868. doi: 10.12890/2024_004868.

eCollection 2024.

PMID: 39651392 [Free PMC article.](#) Otettu 14.2.25

Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with **tocilizumab**: a case report and review of the literature.

Saiki R, Katayama K, Hirabayashi Y, Oda K, Fujimoto M, Murata T, Nakajima A, Dohi K.

BMC Nephrol. 2021 Jun 9;22(1):216. doi: 10.1186/s12882-021-02423-w.

PMID: 34107915 [Free PMC article.](#) Otettu 6.8.21

Successful extension of **tocilizumab** infusion intervals from 4 weeks to 6 or 5 weeks in 90% of RA patients with good response to 4-week intervals.

Saiki O, Uda H.

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):666-670. Epub 2017 Feb 20.

PMID: 28229812

28229812

[Similar articles](#)

Tocilizumab drug levels during pregnancy and lactation: A woman who discontinued **tocilizumab** therapy until the end of the first trimester and resumed it after birth.

Saito J, Yakuwa N, Kaneko K, Goto M, Kawasaki H, Hamamachi Y, Suzuki T, Sago H, Yamatani A, Murashima A.

Obstet Med. 2021 Dec;14(4):260-262. doi: 10.1177/1753495X20966094. Epub 2020 Oct 29.

PMID: 34880942 Otta M

Efficacy and safety of extending intravenous **tocilizumab** intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals.

Saiki O, Uda H.

Rheumatol Int. 2018 Sep 11. doi: 10.1007/s00296-018-4149-3. [Epub ahead of print]

PMID:

30206670 Otettu 25.9.18

[Similar articles](#)

Single intradiscal injection of the interleukin-6 receptor antibody **tocilizumab** provides short-term relief of discogenic low back pain: prospective comparative cohort study.

Sainoh T, Orita S, Miyagi M, Inoue G, Yamauchi K, Suzuki M, Sakuma Y,, Oikawa Y, Inage K, Sato J, Nakata Y, Aoki Y, Takahashi K, Ohtori S.

J Orthop Sci. 2016 Jan;21(1):2-6. doi: 10.1016/j.jos.2015.10.005. Epub 2015 Nov 19.

PMID: ei ole M

26755382

[Similar articles](#)

Role of *IL6R* Genetic Variants in Predicting Response to **Tocilizumab** in Patients with Rheumatoid Arthritis.

Sainz L, Riera P, Moya P, Bernal S, Casademont J, Díaz-Torné C, Millán AM, Park HS, Lasa A, Corominas H.

Pharmaceutics. 2022 Sep 14;14(9):1942. doi: 10.3390/pharmaceutics14091942.

PMID: 36145690 [Free PMC article.](#) Otettu 3.6.23

[A case of rheumatoid arthritis and limited systemic sclerosis overlap successfully treated with **tocilizumab** for arthritis and concomitant generalized lymphadenopathy and primary biliary cirrhosis.](#)

Saito E, Sato S, Nogi S, Sasaki N, Chinen N, Honda K, Wakabayashi T, Yamada C, Nakamura N, Suzuki Y.

Case Rep Rheumatol. 2014;2014:386328. doi: 10.1155/2014/386328. Epub 2014 Apr 15.

PMID:

24839573 [Kokotekstinä](#) Otettu 25.7.15

[PubMed]

[Free PMC Article](#)

[Related citations](#)

Differences in the strength of inhibition of interleukin-6 signalling by subcutaneous sarilumab and **tocilizumab** in rheumatoid arthritis patients.

Saito S, Suzuki K, Yoshimoto K, Kondo Y, Kikuchi J, Hanaoka H, Kaneko Y, Takeuchi T.

Clin Exp Rheumatol. 2022 Dec 15. doi: 10.55563/clinexprheumatol/k0ctlf. Online ahead of print.

PMID: 36533996 Otettu 3.6.23

[Establishment of a measurement system to evaluate breast milk transfer of biological agents using dry filter paper: A multi-institutional study.](#)

Saito J, Yakuwa N, Hosokawa Y, Hamada H, Suzuki T, Sago H, Kaneko K, Yamatani A, Murashima A.

Br J Clin Pharmacol. 2023 Aug 7. doi: 10.1111/bcp.15876. Online ahead of print.

PMID: 37548054 Otta M

[Novel germline STAT3 gain-of-function mutation causes autoimmune diseases and severe growth failure.](#)

Saito K, Fujimoto M, Funajima E, Serada S, Ohkawara T, Ishihara M, Yamada M, Suzuki H, Miya F, Kosaki K, Fujieda M, Naka T.

J Allergy Clin Immunol Glob. 2024 Jul 26;3(4):100312. doi: 10.1016/j.jacig.2024.100312. eCollection 2024 Nov.

PMID: 39253104 [Free PMC article.](#) Otettu 26.11.24

[A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.](#)

Saito S, Suzuki K, Yoshimoto K, Kaneko Y, Matsumoto Y, Yamaoka K, Takeuchi T.

Arthritis Res Ther. 2017 Oct 17;19(1):231. doi: 10.1186/s13075-017-1434-6.

PMID:

29041951 Otettu 5.4.18

[Free PMC Article](#)

[Similar articles](#)

Utility of Dose Frequency Adjustment in **Tocilizumab** Administration for Rheumatoid Arthritis.

Saito S, Kaneko Y, Izumi K, Takeuchi T.

J Rheumatol. 2017 May;44(5):553-557. doi: 10.3899/jrheum.161047. Epub 2017 Mar 15.

PMID:

28298563 Otettu 4.5.18

[Similar articles](#)

Tocilizumab concentrations in maternal serum and breast milk during breastfeeding and a safety assessment in infants: a case study.

Saito J, Yakuwa N, Takai C, Nakajima K, Kaneko K, Goto M, Ishikawa Y, Murashima A.

Rheumatology (Oxford). 2018 Aug 1;57(8):1499-1501. doi: 10.1093/rheumatology/key091. No abstract available.

PMID:

29635528 Otettu 25.9.18

[Similar articles](#)

Clinical application of the dried milk spot method for measuring **tocilizumab** concentrations in the breast milk of patients with rheumatoid **arthritis**.

Saito J, Yakuwa N, Kaneko K, Nakajima K, Takai C, Goto M, Yamatani A, Murashima A.

Int J Rheum Dis. 2019 Jun;22(6):1130-1137. doi: 10.1111/1756-185X.13557. Epub 2019 Apr 10.

PMID: 30968569 Otta M

Tocilizumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk and infant serum.

Saito J, Yakuwa N, Kaneko K, Takai C, Goto M, Nakajima K, Yamatani A, Murashima A. Rheumatology (Oxford). 2019 Aug 1;58(8):1505-1507. doi: 10.1093/rheumatology/kez100. PMID: 30945743 No abstract available. Otettu 2.11.20

Interrupting **tocilizumab** therapy-induced psoriasis-like eruption in a patient with rheumatoid **arthritis** and Crohn's disease.

Saito Y, Hayashi S, Gonmori T, Hamasaki Y, Igawa K. Int J Dermatol. 2020 May;59(5):e159-e160. doi: 10.1111/ijd.14809. Epub 2020 Feb 7. PMID: 32034760 No abstract available. Otta M

Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study.

Saito S, Okuyama A, Okada Y, Shibata A, Sakai R, Kurasawa T, Kondo T, Takei H, Amano K. Rheumatology (Oxford). 2020 Jul 1;59(7):1617-1621. doi: 10.1093/rheumatology/kez511. PMID: 31665468 Otettu 9.1.21

[Successful treatment of adult-onset Still's disease with **tocilizumab** monotherapy: two case reports and literature review.](#)

Sakai R, Nagasawa H, Nishi E, Okuyama A, Takei H, Kurasawa T, Kondo T, Nishimura K, Shirai Y, Ito T, Kameda H, Takeuchi T, Amano K.

Clin Rheumatol. 2012 Mar;31(3):569-74. doi: 10.1007/s10067-011-1917-9. Epub 2012 Jan 4. Review.

PMID:

22215118

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

Select item 24392296705.

[Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.](#)

Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M; REAL Study Group.

Ann Rheum Dis. 2012 Nov;71(11):1820-6. doi: 10.1136/annrheumdis-2011-200838. Epub 2012 Apr 13.

PMID:

22504558

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Corticosteroid- and cyclophosphamide-free treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis using **tocilizumab**.](#)

Sakai R, Shibata A, Chino K, Kondo T, Okuyama A, Takei H, Amano K.

Mod Rheumatol. 2015 Mar 4:1-9. [Epub ahead of print] No abstract available.

PMID:

25736354

[PubMed - as supplied by publisher] Ei ole M

[Related citations](#)

[Head-to-head comparison of the safety of **tocilizumab** and tumor necrosis factor inhibitors in rheumatoid arthritis patients \(RA\) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety \(REAL\) registry.](#)

Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hayashi T, Sugihara T, Dobashi H, Yasuda S, Sawada T, Ezawa K, Ueda A, Fujii T, Migita K, Miyasaka N, Harigai M; REAL Study Group. Arthritis Res Ther. 2015 Mar 23;17(1):74. doi: 10.1186/s13075-015-0583-8.

PMID:

25880658 Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

[Corticosteroid-free treatment of **tocilizumab** monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial.](#)

Sakai R, Kondo T, Kikuchi J, Shibata A, Chino K, Okuyama A, Takei H, Amano K.

Mod Rheumatol. 2016 Nov;26(6):900-907. doi: 10.3109/14397595.2016.1160968. Epub 2016 Apr 21.

PMID: ei ole M

26934300

[Similar articles](#)

[TAFRO syndrome successfully treated with **tocilizumab**: A case report and systematic review.](#)

Sakai K, Maeda T, Kuriyama A, Shimada N, Notohara K, Ueda Y.

Mod Rheumatol. 2016 Feb 17:1-6. [Epub ahead of print]

PMID: ei ole M

26886414

[Similar articles](#)

Current clinical evidence of **tocilizumab** for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review.

Sakai R, Kondo T, Kurasawa T, Nishi E, Okuyama A, Chino K, Shibata A, Okada Y, Takei H, Nagasawa H, Amano K.

Clin Rheumatol. 2017 Oct;36(10):2383-2392. doi: 10.1007/s10067-017-3752-0. Epub 2017 Jul 21. Review.

PMID:

28733791 Otettu 2.5.2018

[Similar articles](#)

An anterior mediastinal lesion in TAFRO syndrome showing complete remission after glucocorticoid and **tocilizumab** therapy.

Sakashita K, Murata K, Inagaki Y, Takamori M.

Respirol Case Rep. 2016 Jul 4;4(5):e00173. doi: 10.1002/rcr2.173. eCollection 2016 Sep.

Otettu 22.9.18 Otettu 16.7.22

27516889

Free PMC Article

[Similar articles](#)

242.

[**Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis.**](#)

Sakaue S, Sumitomo S, Kubo K, Fujio K, Yamamoto K.

Rheumatology (Oxford). 2014 Aug;53(8):1529-30. doi: 10.1093/rheumatology/keu008. Epub 2014 Mar 7. No abstract available.

PMID:

24609062

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

Safety and efficacy of **tocilizumab** for rheumatoid arthritis: a systematic review and meta-analysis of clinical trial studies.

Saki A, Rajaei E, Rahim F.

Reumatologia. 2021;59(3):169-179. doi: 10.5114/reum.2021.107026. Epub 2021 Jul 11.

PMID: 34538944 [Free PMC article.](#) Otettu 16.7.22

Tocilizumab: Another medication related to osteonecrosis of the jaws? A case report and literature review.

Sakkas A, Heil S, Kargus S, Rebel M, Mischkowski RA, Thiele OC.

GMS Interdiscip Plast Reconstr Surg DGPW. 2021 Apr 14;10:Doc03. doi: 10.3205/iprs000153. eCollection 2021.

PMID: 33928006 [Free PMC article.](#) Otettu 6.8.21

[Spotlight on **tocilizumab** and its potential in the treatment of systemic sclerosis.](#)

Sakkas LI.

Drug Des Devel Ther. 2016 Aug 29;10:2723-8. doi: 10.2147/DDDT.S99696. eCollection 2016. Review.

PMID: Otettu 5.4.18

27621593

Free PMC Article

[Similar articles](#)

Clinical usefulness of longitudinal IL-6 monitoring in a patient with Takayasu aortitis receiving **tocilizumab**.

Sakumura N, Irabu H, Inoue N, Mizuta M, Shimizu M.

Rheumatology (Oxford). 2020 Jan 1;59(1):252-254. doi: 10.1093/rheumatology/kez245.

PMID: 31280300 Otettu 9.1.21

Sustained response to **tocilizumab** in a patient with relapsing polychondritis complicated by aortitis.

Sallés M, Mínguez S, Ros S, Tuneu R, Gelman SM.

Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):223. Epub 2017 Feb 22. Review. No abstract available.

PMID:

28229816 Otettu 5.4.18

[Similar articles](#)

[An autoinflammatory neurological disease due to interleukin 6 hypersecretion.](#)

Salsano E, Rizzo A, Bedini G, Bernard L, Dall'olio V, Volorio S, Lazzaroni M, Ceccherini I, Lazarevic D, Cittaro D, Stupka E, Pattera R, Farina L, Savoiaro M, Pareyson D, Sciacca FL. J Neuroinflammation. 2013 Feb 21;10:29. doi: 10.1186/1742-2094-10-29.

PMID:

23432807

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

[Tocilizumab: a novel therapy for patients with large-vessel vasculitis.](#)

Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, Pulsatelli L, Meliconi R, Boiardi L.

Rheumatology (Oxford). 2012 Jan;51(1):151-6. doi: 10.1093/rheumatology/ker296. Epub 2011 Nov 10.

PMID:

22075063

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

[Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF- \$\alpha\$ blockers.](#)

Salvarani C, Magnani L, Catanoso MG, Pipitone N, Versari A, Dardani L, Pulsatelli L, Meliconi R, Boiardi L.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S90-3. Epub 2012 May 11.

PMID:

22410150

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

Management of large-vessel vasculitis.

Salvarani C, Hatemi G.

Curr Opin Rheumatol. 2019 Jan;31(1):25-31. doi: 10.1097/BOR.0000000000000561.

PMID: 30461542 Otta M

[Update on giant cell arteritis.](#)

Sammel AM, Fraser CL.

Curr Opin Ophthalmol. 2018 Aug 22. doi: 10.1097/ICU.0000000000000528. [Epub ahead of print]

PMID:

30138144 Otettu 25.9.18

[Similar articles](#)

Improvement of Treg immune response after treatment with **tocilizumab** in giant cell arteritis.

Samson M, Greigert H, Ciudad M, Gerard C, Ghesquière T, Trad M, Corbera-Bellalta M, Genet C, Ouandji S, Cladière C, Thebault M, Ly KH, Liozon E, Maurier F, Bienvenu B, Terrier B, Guillevin L, Charles P, Quipourt V, Devilliers H, Gabrielle PH, Creuzot-Garcher C, Tarris G, Martin L, Saas P, Audia S, Cid MC, Bonnotte B.

Clin Transl Immunology. 2021 Sep 12;10(9):e1332. doi: 10.1002/cti2.1332. eCollection 2021.

PMID: 34532040 **Free PMC article.** Otettu 16.7.22

[Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis.](#)

Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, Ornetti P, Maillefert JF, Miossec P, Bonnotte B.

Arthritis Rheum. 2012 Aug;64(8):2499-503. doi: 10.1002/art.34477.

PMID:

22488116

[PubMed - indexed for MEDLINE] [Kokotekstinä](#) Otettu 25.7.2015

[Free Article](#)

[Related citations](#)

170.

[Does **tocilizumab** indeed reduce the frequency of Th17 cells? Comment on the article by Thiolat et al.](#)

Samson M, Audia S, Ornetti P, Maillefert JF, Janikashvili N, Bonnotte B.

Arthritis Rheumatol. 2014 Sep;66(9):2639-40. doi: 10.1002/art.38718. No abstract available.

PMID:

24891312

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Targeted treatment in Takayasu arteritis.](#)

Samson M, Greigert H, Ramon A, Bonnotte B.

Joint Bone Spine. 2022 Mar;89(2):105338. doi: 10.1016/j.jbspin.2021.105338. Epub 2021 Dec 30.

PMID: 34974195 Otta M

[Biological treatments in giant cell arteritis & Takayasu arteritis.](#)

Samson M, Espígol-Frigolé G, Terrades-García N, Prieto-González S, Corbera-Bellalta M, Alba-Rovira R, Hernández-Rodríguez J, Audia S, Bonnotte B, Cid MC.

Eur J Intern Med. 2017 Nov 13. pii: S0953-6205(17)30434-X. doi: 10.1016/j.ejim.2017.11.003. [Epub ahead of print] Review.

PMID:

29146018 Otettu 4.5.18

[Similar articles](#)

[Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.](#)

Samson M, Devilliers H, Ly KH, Maurier F, Bienvenu B, Terrier B, Charles P, Guillevin L, Besancenot JF, Liozon E, Fauchais AL, Loffroy R, Binquet C, Audia S, Seror R, Mariette X, Bonnotte B.

Eur J Intern Med. 2018 Jul 24. pii: S0953-6205(18)30240-1. doi: 10.1016/j.ejim.2018.06.008. [Epub ahead of print]

PMID:

30054122 Otettu 25.9.18

[Similar articles](#)

[Targeting interleukin-6 pathways in giant cell arteritis management: A narrative review of evidence.](#)

Samson M, Dasgupta B, Sammel AM, Salvarani C, Pagnoux C, Hajj-Ali R, Schmidt WA, Cid MC. Autoimmun Rev. 2025 Jan 31;24(2):103716. doi: 10.1016/j.autrev.2024.103716. Epub 2024 Dec 5.
PMID: 39644981 [Free article](#). Review. Otettu 14.2.25

Analysis of IL-6 measurement in patients with GCA treated with **tocilizumab** should consider concomitant treatment with prednisone.

Samson M, Bonnotte B.

Ann Rheum Dis. 2020 Aug;79(8):e102. doi: 10.1136/annrheumdis-2019-215697. Epub 2019 May 29.

PMID: 31142476 Otettu 9.1.21

T-cell immune response predicts the risk of critical SARS-Cov2 infection in hospitalized COVID-19 patients.

Samson M, Nicolas B, Ciudad M, Greigert H, Guilhem A, Cladiere C, Straub C, Blot M, Piroth L, Rogier T, Devilliers H, Manckoundia P, Ghesquiere T, Francois S, Lakomy D, Audia S, Bonnotte B. Eur J Intern Med. 2022 Jun 3:S0953-6205(22)00213-8. doi: 10.1016/j.ejim.2022.06.001. Online ahead of print.

PMID: 35690570 [Free PMC article](#). Otettu 16.7.22

[Prediction of therapeutic responses to **tocilizumab** in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray.](#)

Sanayama Y, Ikeda K, Saito Y, Kagami S, Yamagata M, Furuta S, Kashiwakuma D, Iwamoto I, Umibe T, Nawata Y, Matsumura R, Sugiyama T, Sueishi M, Hiraguri M, Nonaka K, Ohara O, Nakajima H.

Arthritis Rheumatol. 2014 Jun;66(6):1421-31. doi: 10.1002/art.38400.

PMID:

24591094

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

Anti-IL-6 Receptor **Tocilizumab** in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients.

Sánchez-Bilbao L, Martínez-López D, Revenga M, López-Vázquez Á, Valls-Pascual E, Atienza-Mateo B, Valls-Espinosa B, Maiz-Alonso O, Blanco A, Torre-Salaberri I, Rodríguez-Méndez V, García-Aparicio Á, Veroz-González R, Jovaní V, Peiteado D, Sánchez-Orgaz M, Tomero E, Toyos-Sáenz de Miera FJ, Pinillos V, Aurrecoechea E, Mora Á, Conesa A, Fernández-Prada M, Troyano JA, Calvo-Río V, Demetrio-Pablo R, González-Mazón Í, Hernández JL, Castañeda S, González-Gay MÁ, Blanco R.

J Clin Med. 2020 Aug 31;9(9):2816. doi: 10.3390/jcm9092816.

PMID: 32878150 [Free PMC article.](#) Otettu 9.1.21

[Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving **tocilizumab**.](#)

Sánchez-Montalvá A, Sellarés-Nadal J, Espinosa-Pereiro J, Fernández-Hidalgo N, Pérez-Hoyos S, Salvador F, Durà X, Miarons M, Antón A, Eremiev-Eremiev S, Sempere-González A, Monforte-Pallarés A, Bosch-Nicolau P, Augustin S, Sampol J, Guillén-Del-Castillo A, Almirante B. Med Clin (Engl Ed). 2022 Jun 10;158(11):509-518. doi: 10.1016/j.medcle.2021.06.023. Epub 2022 Jun 18.

PMID: 35755602 [Free PMC article.](#) Otettu 16.7.22

Need and value of targeted immunosuppressive therapy in giant cell arteritis.

Sandovici M, van der Geest N, van Sleen Y, Brouwer E.

RMD Open. 2022 Feb;8(1):e001652. doi: 10.1136/rmdopen-2021-001652.

PMID: 35149602 [Free PMC article](#). Otettu 16.7.22

Tocilizumab in the treatment of adult rheumatoid arthritis.

Sanmartí R, Ruiz-Esquide V, Bastida C, Soy D.

Immunotherapy. 2018 Mar 1;10(6):447-464. doi: 10.2217/imt-2017-0173. Epub 2018 Mar 2.

PMID:

29495891 ei ole M

[Similar articles](#)

Reducing or Maintaining the Dose of Subcutaneous **Tocilizumab in Patients With Rheumatoid Arthritis** in Clinical Remission: A Randomized, Open-Label Trial.

Sanmarti R, Veale DJ, Martin-Mola E, Escudero-Contreras A, González C, Ercole L, Alonso R, Fonseca JE; ToSpace Study Group.

Arthritis Rheumatol. 2019 Oct;71(10):1616-1625. doi: 10.1002/art.40905. Epub 2019 Sep 24.

PMID: 31087542 [Free article](#). Clinical Trial. Otta M

[An Unusual Case of HHV-8 Negative, Idiopathic, Multicentric Castleman Disease Following Chronic Lymphocytic Leukaemia.](#)

Sansen PY, Vellemans H, Depaus J, Fervaille C, Krug B, Sonet A, Collinge E.

Eur J Case Rep Intern Med. 2024 Aug 5;11(9):004688. doi: 10.12890/2024_004688. eCollection 2024.

PMID: 39247244 [Free PMC article.](#) Otettu 26.11.24

[ADA ETA BIO2021: real-world evaluation of adherence, persistence, and cost-effectiveness of originator and biosimilar biologic drugs in the treatment of rheumatoid arthritis: a multicenter study in Italy.](#)

Santoleri F, Lasala R, Abrate P, Pestrin L, Pasut E, Modesti G, Musicco F, Fulgenzio C, Zuzolo E, Pieri G, Roperti M, Gazzola P, Gambera M, Martignoni I, Montresor V, De Vita F, Guarino F, Grossi L, Di Fabio L, Roberti C, Spoltore C, Tinari G, De Rosa S, Giannini R, Langella R, Mingolla G, Piccoli M, Costantini A.

Curr Med Res Opin. 2023 Dec;39(12):1729-1735. doi: 10.1080/03007995.2023.2287600. Epub 2023 Dec 15.

PMID: 37994874 Otta M

Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid **arthritis** patients who discontinued a first TNF inhibitor.

Santos-Faria D, Tavares-Costa J, Eusébio M, Leite Silva J, Ramos Rodrigues J, Sousa-Neves J, Duarte AC, Lopes C, Valido A, Dinis J, Freitas J, Santiago M, Ferreira R, Ganhão S, Miranda L, Peixoto D, Teixeira F, Alcino S, Afonso C, Santos MJ.

Acta Reumatol Port. 2019 Apr-Jun;44(2):103-113.

PMID: 31243259 English. Otettu 2.11.20

[Tocilizumab treatment leads to a rapid and sustained increase in Treg cell levels in rheumatoid arthritis patients: comment on the article by Thiolat et al.](#)

Sarantopoulos A, Tselios K, Gkougkourelas I, Pantoura M, Georgiadou AM, Boura P.
Arthritis Rheumatol. 2014 Sep;66(9):2638. doi: 10.1002/art.38714. No abstract available.

PMID:

24891239

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

Disease progression of Takayasu arteritis in two patients treated with **tocilizumab**.

Sanchez-Alvarez C, Koster M, Duarte-García A, Warrington KJ.

Ann Rheum Dis. 2020 Feb;79(2):e21. doi: 10.1136/annrheumdis-2018-214642. Epub 2018 Dec 8.

PMID: 30530823 Otettu 9.1.21

Complexity of Inflammation in the Trajectory of Vascular Disease: Interleukin 6 and Beyond.

Sano M.

Ann Vasc Dis. 2023 Mar 25;16(1):8-16. doi: 10.3400/avd.ra.23-00003.

PMID: 37006867 [Free PMC article.](#) Otettu 3.6.23

703.

[Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with **tocilizumab**: the SPARE-1 study.](#)

Saraux A, Rouanet S, Flipo RM, Poncet JC, Fardellone P, Hilliquin P, Idier I, Cantagrel A.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):303-10. Epub 2016 Mar 3.

PMID: Otettu 5.4.18

26941130

[Similar articles](#)

[A case of **tocilizumab**-induced leukoencephalopathy with a reversible clinical course.](#)

Sasaki R, Hishikawa N, Nomura E, Omote Y, Takemoto M, Yamashita T, Hatanaka N, Higashi Y, Abe K.

Intern Med. 2020 Sep 30. doi: 10.2169/internalmedicine.5288-20. Online ahead of print.

PMID: 32999229 Otettu 2.11.20

[Comment on: Comparative effectiveness of abatacept, rituximab, **tocilizumab** and TNFi biologics in RA: results from the nationwide Swedish register.](#)

Satış H, Can GE, Salman RB, Güler AA, Karadeniz H, Tufan A.
Rheumatology (Oxford). 2019 Aug 1;58(8):1509-1510. doi: 10.1093/rheumatology/kez170.
PMID: 31056679 Otettu 9.1.21

Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993;53:851–6.
Otettu 2.5.2018

[Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis.](#)

Sato H, Sakai T, Sugaya T., Aoki K, Ishii K, Horizonono H., Abe A, Yamada N, Ishikawa H, Nakazono K, Murasawa A, Gejyo F.
Clin Rheumatol. 2009 Sep;28(9):1113-6. doi: 10.1007/s10067-009-1185-0. Epub 2009 May 13.
PMID:

19437089

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis.](#)

Sato T, Minakuchi S, Mochizuki M, Takeuchi M.
Clin Ophthalmol. 2014 Jan 8;8:187-90. doi: 10.2147/OPTH.S54929. eCollection 2014.
PMID:

24531503 Otettu 24.7.15

[PubMed]

[Free PMC Article](#)

[Related citations](#)

[Tocilizumab treatment safety in rheumatoid arthritis in a patient with multiple sclerosis: a case report.](#)

Sato H, Kobayashi D, Abe A, Ito S, Ishikawa H, Nakazono K, Murasawa A, Kuroda T, Nakano M, Narita I.

BMC Res Notes. 2014 Sep 12;7:641. doi: 10.1186/1756-0500-7-641.

PMID:

25216562

[PubMed - in process] [Kokotekstinä](#) Otettu 25.7.15

[Free PMC Article](#)

[Related citations](#)

[Treatment of polyarteritis nodosa with **tocilizumab**: a new therapeutic approach?](#)

Saunier A, Issa N, Vandenhende MA, Morlat P, Doutre MS, Bonnet F.

RMD Open. 2017 Jun 29;3(1):e000446. doi: 10.1136/rmdopen-2017-000446. eCollection 2017.

PMID:

28879047 Otettu 5.4.18

[Free PMC Article](#)

[Similar articles](#)

[A Case of Castleman's Disease with a Marked Infiltration of IgG4-Positive Cells in the Renal Interstitium.](#)

Sawada E, Shioda Y, Ogawa K, Iwashita T, Ono Y, Hasegawa H, Maeshima A.

Diagnostics (Basel). 2024 Feb 23;14(5):476. doi: 10.3390/diagnostics14050476.

PMID: 38472948 [Free PMC article.](#) Otettu 15.3.24

244.

[Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still's disease successfully treated with **tocilizumab**.](#)

Savage E, Wazir T, Drake M, Cuthbert R, Wright G.

Rheumatology (Oxford). 2014 Jul;53(7):1352-3. doi: 10.1093/rheumatology/keu019. Epub 2014 Mar 7. No abstract available.

PMID:

24609056

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Assessing trends in cytokine-CYP drug interaction and relevance to drug dosing.](#)

Sawant-Basak A, Olabode D, Dai D, Vishwanathan K, Phipps A.

Drug Metab Dispos. 2024 Feb 21:DMD-MR-2023-001499. doi: 10.1124/dmd.123.001499. Online ahead of print.

PMID: 38383116 [Free article.](#) Otettu 7.3.24

Should **tocilizumab** be the first line treatment for neuromyelitis optica together with rituximab?

Sawaya R, Saab G, Moussa H.

Neurologia. 2020 Nov 8:S0213-4853(20)30310-8. doi: 10.1016/j.nrl.2020.10.007. Online ahead of print.

PMID: 33176917 English, Spanish. No abstract available. Otettu 9.1.21

942.

[Formulary review of 2 new biologic agents: **tocilizumab** for rheumatoid arthritis and **ustekinumab** for plaque psoriasis.](#)

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2010 Jul-Aug;16(6):402-16. Review.

PMID:

20635831

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

702.

[Interstitial granulomatous dermatitis with arthritis responding to **tocilizumab**.](#)

Schanz S, Schmalzing M, Guenova E, Metzler G, Ulmer A, Kötter I, Fierlbeck G.

Arch Dermatol. 2012 Jan;148(1):17-20. doi: 10.1001/archdermatol.2011.341. No abstract available.

PMID:

22250229

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Circulating Baseline CXCR3+Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis.](#)

Scheffler JM, Drevinge C, Lindholm C, Gjertsson I, Lend K, Lund Hetland M, Østergaard M, Uhlig T, Schruppf Heiberg M, Haavardsholm EA, Nurmohamed MT, Lampa J, Sokka-Isler T, Nordström D, Hørslev-Petersen K, Gudbjornsson B, Gröndal G, van Vollenhoven R, Carlsten H, Lorentzon M, Hultgård Ekwall AK, Rudin A, Islander U.

ACR Open Rheumatol. 2024 Oct 16. doi: 10.1002/acr2.11742. Online ahead of print.

PMID: 39411912 [Free article.](#) Otettu 26.11.24

[Tocilizumab.](#)

Scheinecker C, Smolen J, Yasothan U, Stoll J, Kirkpatrick P.

Nat Rev Drug Discov. 2009 Apr;8(4):273-4. doi: 10.1038/nrd2863. No abstract available.

PMID:

19337270

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[The pro- and anti-inflammatory properties of the cytokine interleukin-6.](#)

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S.

Biochim Biophys Acta. 2011 May;1813(5):878-88. doi: 10.1016/j.bbamcr.2011.01.034. Epub 2011 Feb 4. Review.

PMID:

21296109

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

[Monitoring of Epstein-Barr virus \(EBV\)/cytomegalovirus \(CMV\)/varicella-zoster virus \(VZV\) load in patients receiving **tocilizumab** for rheumatoid arthritis.](#)

Scherlinger M, Alain S, Richez C.

Joint Bone Spine. 2018 Mar;85(2):259-260. doi: 10.1016/j.jbspin.2017.02.010. Epub 2017 Mar 28. No abstract available.

PMID:

28363825 Otettu 2.5.2018

[Similar articles](#)

COVID-19 revisiting inflammatory pathways of **arthritis**.

Schett G, Manger B, Simon D, Caporali R.

Nat Rev Rheumatol. 2020 Aug;16(8):465-470. doi: 10.1038/s41584-020-0451-z. Epub 2020 Jun 19.

PMID: 32561873 **Free PMC article**. Review. Otettu 2.11.20

[Takayasu arteritis and NYHA III/IV idiopathic cardiomyopathy: **tocilizumab** proves effective and safe.](#)

Schiavon F, Cuffaro S, Ometto F, Mojoli M, Ramonda R.

Joint Bone Spine. 2014 May;81(3):278-9. doi: 10.1016/j.jbspin.2013.11.008. Epub 2013 Dec 31. No abstract available.

PMID:

24388783

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Integrated safety in **tocilizumab** clinical trials.](#)

Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF.

Arthritis Res Ther. 2011;13(5):R141. doi: 10.1186/ar3455. Epub 2011 Sep 1.

PMID:

21884601

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

[The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis.](#)

Schinnerling K, Aguillón JC, Catalán D, Soto L.

Clin Exp Immunol. 2017 Jul;189(1):12-20. doi: 10.1111/cei.12966. Epub 2017 Apr 20. Review.

PMID:

28369786 Otettu 4.5.18

[Similar articles](#)

Tocilizumab in Large Vessel Vasculitis - Different Routes of Administration.

Schmalzing M, Gadeholt O, Gernert M, Tony HP, Schwaneck EC.

Open Rheumatol J. 2018 Aug 31;12:152-159. doi: 10.2174/1874312901812010152. eCollection 2018.

PMID: 30258504 [Free PMC article.](#) Otettu 2.11.20

[Polymyalgia rheumatica: What's new?\].](#)

Schmidt WA.

Dtsch Med Wochenschr. 2024 Aug;149(17):1051-1055. doi: 10.1055/a-2144-8222. Epub 2024 Aug 15.

PMID: 39146754 German. Otta M

Inflammatory Muscle Pain: Polymyalgia Rheumatica with or without Large Vessel Vasculitis].

Schmidt WA.

Dtsch Med Wochenschr. 2020 Jul;145(13):895-902. doi: 10.1055/a-1074-7685. Epub 2020 Jul 2.

PMID: 32615604 German. Otta M

Intravenous **tocilizumab** for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.

Schmitt C, Brockwell L, Giraudon M, Zucchetto M, Christ L, Bannert B, Daikeler T, Villiger PM.

Arthritis Res Ther. 2022 Jun 4;24(1):133. doi: 10.1186/s13075-022-02815-9.

PMID: 35659282 [Free PMC article](#). Otettu 16.7.22

[Disease-drug-drug interaction involving **tocilizumab** and simvastatin in patients with rheumatoid arthritis.](#)

Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S.

Clin Pharmacol Ther. 2011 May;89(5):735-40. doi: 10.1038/clpt.2011.35. Epub 2011 Mar 23.

Erratum in: Clin Pharmacol Ther. 2011 Sep;90(3):479. Dosage error in article text.

PMID:

21430660

[PubMed - indexed for MEDLINE] ei ole M

[Related citations](#)

680.

[Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis.](#)

Schmitt C, Kuhn B, Zhang X, Kivitz A, Grange S.
Int J Clin Pharmacol Ther. 2012 Mar;50(3):218-23.

PMID:

22373834

[PubMed - indexed for MEDLINE] ei ole M

[Related citations](#)

[Comparative effectiveness and safety of biological treatment options after tumour necrosis factor \$\alpha\$ inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.](#)

Schoels M, Aletaha D, Smolen JS, Wong JB.

Ann Rheum Dis. 2012 Aug;71(8):1303-8. doi: 10.1136/annrheumdis-2011-200490. Epub 2012 Jan 30. Review.

PMID:

22294630

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.](#)

Schoels MM, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Nishimoto N, Smolen JS.

Ann Rheum Dis. 2013 Apr;72(4):583-9. doi: 10.1136/annrheumdis-2012-202470. Epub 2012 Nov 10. Review. Erratum in: Ann Rheum Dis. 2013 Jun;72(6):1110. Murikama, Miho M [corrected to Murakami, Miho].

PMID:

23144446

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

Divergent regulatory T cell responses to high-dose methylprednisolone and **tocilizumab** in giant cell arteritis.

Scholz GA, Fux M, Christ L, Iype J, Banz Y, Villiger PM.

J Autoimmun. 2022 Dec;133:102909. doi: 10.1016/j.jaut.2022.102909. Epub 2022 Sep 15.

PMID: 36115211 [Free article](#). Otettu 3.6.23.

COVID-19 Induced Cardiomyopathy Successfully Treated with **Tocilizumab**.

Schreiber A, Elango K, Soussu C, Fakhra S, Asad S, Ahsan C.

Case Rep Cardiol. 2022 Apr 6;2022:9943937. doi: 10.1155/2022/9943937. eCollection 2022.

PMID: 35402051 [Free PMC article](#). Otettu 17.7.22

Pharmacokinetics and pharmacodynamics of a proposed **tocilizumab** biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.

Schwabe C, Illes A, Ullmann M, Ghori V, Vincent E, Petit-Frere C, Monnet J, Racault AS, Wynne C.

Expert Rev Clin Immunol. 2022 May;18(5):533-543. doi: 10.1080/1744666X.2022.2060204.

Epub 2022 Apr 10.

PMID: 35354411 Clinical Trial. Otettu 17.7.22

[Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study.](#)

Schönau V, Roth J, Tascilar K, Corte G, Manger B, Rech J, Schmidt D, Cavallaro A, Uder M, Crescentini F, Boiardi L, Casali M, Spaggiari L, Galli E, Kuwert T, Versari A, Salvarani C, Schett G, Muratore F.

Rheumatology (Oxford). 2021 Aug 2;60(8):3851-3861. doi: 10.1093/rheumatology/keab332.

PMID: 33831144 Otettu 6.8.21

[Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein \(a\) levels in human subjects with rheumatoid diseases.](#)

Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, Laudes M.

PLoS One. 2010 Dec 13;5(12):e14328. doi: 10.1371/journal.pone.0014328.

PMID:

21179199

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

[T cells, natural killer cells, and \$\gamma\delta\$ T cells in a large patient cohort with rheumatoid arthritis: influence of age and anti-rheumatic therapy.](#)

Schwaneck EC, Renner R, Junker L, Tony HP, Kleinert S, Gernert M, Schmalzing M, Gadeholt O.

Scand J Rheumatol. 2020 Jan;49(1):8-12. doi: 10.1080/03009742.2019.1634755. Epub 2019 Sep 26.
PMID: 31556339 Otta M

[The Use of Biologic Therapies in Uveitis.](#)

Schwartzman S, Schwartzman M.

Clin Rev Allergy Immunol. 2014 Nov 29. [Epub ahead of print]

PMID:

25431348

[PubMed - as supplied by publisher] Ei ole M

[Related citations](#)

694.

[\[Rheumatoid arthritis and multiple myeloma as comorbidity. Is tocilizumab a therapy option?\].](#)

Schütz N, Märker-Hermann E.

Z Rheumatol. 2012 Jan;71(1):78-82. doi: 10.1007/s00393-011-0931-2. German.

PMID:

22286359

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Follow-up ultrasound examination in patients with newly diagnosed giant cell arteritis.](#)

Schäfer VS, Dejaco C, Karakostas P, Behning C, Brossart P, Burg LC.

Rheumatology (Oxford). 2024 Feb 15;keae098. doi: 10.1093/rheumatology/keae098. Online ahead of print.

PMID: 38366635 Otta M

Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis.

Schäfer M, Meißner Y, Kekow J, Berger S, Remstedt S, Manger B, Listing J, Strangfeld A, Zink A. Rheumatology (Oxford). 2020 Aug 1;59(8):1916-1926. doi: 10.1093/rheumatology/kez535. PMID: 31745566 [Free PMC article](#). Otettu 9.1.21

776.

[Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis.](#)

Sciascia S, Rossi D, Roccatello D.

J Rheumatol. 2011 Sep;38(9):2080-1. doi: 10.3899/jrheum.110496. No abstract available.

PMID:

21885526

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Tocilizumab: A Review in Rheumatoid Arthritis.](#)

Scott LJ.

Drugs. 2017 Nov;77(17):1865-1879. doi: 10.1007/s40265-017-0829-7. Erratum in: [Drugs. 2017 Dec 19::](#).

PMID:

29094311 Otettu 5.4.18

[Free PMC Article](#)

[Similar articles](#)

Efficacy and safety of **tocilizumab** in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool.

Sebastian A, Kayani A, Prieto-Pena D, Tomelleri A, Whitlock M, Mo J, van der Geest N, Dasgupta B.

RMD Open. 2020 Nov;6(3):e001417. doi: 10.1136/rmdopen-2020-001417.

PMID: 33161376 [Free article](#). Otettu 9.1.21

Halo score (temporal artery, its branches and axillary artery) as a diagnostic, prognostic and disease monitoring tool for Giant Cell Arteritis (GCA).

Sebastian A, van der Geest KSM, Coath F, Gondo P, Kayani A, Mackerness C, Hadebe B, Innes S, Jackson J, Dasgupta B.

BMC Rheumatol. 2020 Aug 18;4:35. doi: 10.1186/s41927-020-00136-5. eCollection 2020.

PMID: 32821876 [Free PMC article](#). Otettu 9.1.21

.

[Tocilizumab: the first interleukin-6-receptor inhibitor.](#)

Sebba A.

Am J Health Syst Pharm. 2008 Aug 1;65(15):1413-8. doi: 10.2146/ajhp070449. Review.

PMID:

18653811

[PubMed - indexed for MEDLINE] ei aukea M

[Related citations](#)

Quantitative ultrasound to monitor the vascular response to **tocilizumab** in giant cell arteritis.
Seitz L, Christ L, Lötscher F, Scholz G, Sarbu AC, Bütikofer L, Kollert F, Schmidt WA, Reichenbach S, Villiger PM.

Rheumatology (Oxford). 2021 Jun 12;keab484. doi: 10.1093/rheumatology/keab484. Online ahead of print.

PMID: 34117737 [Free article](#). Otettu 6.8.21

[Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series.](#)

Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM.

Swiss Med Wkly. 2011 Jan 17;141:w13156. doi: 10.4414/smw.2011.13156.

PMID:

21243547

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

[Medication-related osteonecrosis of the jaw in a patient with rheumatoid arthritis with suspected involvement of methotrexate and **tocilizumab**.](#)

Seki K, Kobayashi A, Takahashi N, Kamimoto A.

J Dent Sci. 2024 Oct;19(4):2428-2429. doi: 10.1016/j.jds.2024.07.024. Epub 2024 Jul 31.

PMID: 39347083 [Free PMC article](#). Otettu 26.11.24

Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience.

Sellner J, Sitte HH, Rommer PS.

Drug Discov Today. 2021 Mar 27:S1359-6446(21)00154-9. doi: 10.1016/j.drudis.2021.03.018. Online ahead of print.

PMID: 33781948 [Free article](#). Review. Otettu 6.8f.21

[New treatments for inflammatory rheumatic disease.](#)

Selmi C, Generali E, Massarotti M, Bianchi G, Sciré CA.

Immunol Res. 2014 Dec;60(2-3):277-88. doi: 10.1007/s12026-014-8565-5.

PMID:

25381481

[PubMed - in process] [Ei ole M](#)

[Related citations](#)

[Safety issues and concerns of new immunomodulators in rheumatology.](#)

Selmi C, Ceribelli A, Naguwa SM, Cantarini L, Shoenfeld Y.

Expert Opin Drug Saf. 2015 Mar;14(3):389-99. doi: 10.1517/14740338.2015.993605. Epub 2014 Dec 18.

PMID:

25518908

[PubMed - in process] [Ei ole M](#)

[Related citations](#)

The Treatment of COVID-19 Purgatory Syndrome With **Tocilizumab** and Steroids.

Selvaraj V, Finn A, Li J, Dapaah-Afriyie K.

Cureus. 2022 Feb 25;14(2):e22614. doi: 10.7759/cureus.22614. eCollection 2022 Feb.

PMID: 35371682 [Free PMC article.](#) [Otetu 17.7.22](#)

208.

[Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.](#)

Semerano L, Thiolat A, Minichiello E, Clavel G, Bessis N, Boissier MC.

Expert Opin Investig Drugs. 2014 Jul;23(7):979-99. doi: 10.1517/13543784.2014.912276. Epub 2014 Apr 26. Review.

PMID:

24766460

[PubMed - indexed for MEDLINE] [Ei ole M](#)

[Related citations](#)

[Treatment of childhood-onset Takayasu arteritis: switching between anti-TNF and anti-IL-6 agents.](#)

Sener S, Basaran O, Akca UK, Atalay E, Cuceoglu MK, Balik Z, Aliyev E, Bayindir Y, Batu ED, Hazirolan T, Bilginer Y, Ozen S.

Rheumatology (Oxford). 2022 Mar 9;keac149. doi: 10.1093/rheumatology/keac149. Online ahead of print.

PMID: 35262635 [Otta M](#)

[Use of biologic drug in the treatment of localized scleroderma and systemic sclerosis in children: A scoping review.](#)

Sener S, Batu ED.

Semin Arthritis Rheum. 2025 Jan 29;71:152634. doi: 10.1016/j.semarthrit.2025.152634. Online ahead of print.

PMID: 39938346 Review. Otta M

[**Tocilizumab** \(anti-IL-6\) treatment for AA renal amyloidosis in a patient with advanced chronic kidney disease, a case report.](#)

Seneschall C, Law S, Roufosse C, Woodham S, Kousios A.

J Nephrol. 2024 Jan 11. doi: 10.1007/s40620-023-01845-z. Online ahead of print.

PMID: 38206475 Otta M

[Primary \(Month-6\) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of **Tocilizumab** in Patients With Noninfectious Uveitis.](#)

Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, Hanout M, Hassan M, Afridi R, Agarwal A, Halim MS, Do DV, Nguyen QD.

Am J Ophthalmol. 2017 Nov;183:71-80. doi: 10.1016/j.ajo.2017.08.019. Epub 2017 Sep 5.

PMID:

28887113 Otettu 2.5.2018

[Similar articles](#)

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid **arthritis**.

Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma JW, Burmester GR, de Wit M, Falzon L, Landewé R.

Ann Rheum Dis. 2020 Jun;79(6):760-770. doi: 10.1136/annrheumdis-2019-216653. Epub 2020 Feb 7.

PMID: 32033941 Otettu 2.11.20

[Remission of nephrotic syndrome due to AA-amyloidosis, complicating familial Mediterranean fever, with **tocilizumab**.](#)

Serelis J, Christaki S, Skopouli FN.

Clin Exp Rheumatol. 2015 Jan 9. [Epub ahead of print]

PMID:

25572486

[PubMed - as supplied by publisher] ei löytynyt

[Related citations](#)

The use of **tocilizumab** and tofacitinib in patients with resolved hepatitis B infection: a case series.

Serling-Boyd N, Mohareb AM, Kim AY, Hyle EP, Wallace ZS.

Ann Rheum Dis. 2020 Jul 30;annrheumdis-2020-218289. doi:

10.1136/annrheumdis-2020-218289. Online ahead of print.

PMID: 32732241 Otettu 9.1.21

Recent advances in the diagnosis and management of giant cell arteritis.

Serling-Boyd N, Stone JH.

Curr Opin Rheumatol. 2020 May;32(3):201-207. doi: 10.1097/BOR.0000000000000700.

PMID: 32168069 [Free PMC article.](#) Otettu 9.1.21

Management of primary vasculitides with biologic and novel small molecule medications.

Serling-Boyd N, Wallace ZS.

Curr Opin Rheumatol. 2021 Jan;33(1):8-14. doi: 10.1097/BOR.0000000000000756.

PMID: 33164993 Otta M

Response to: 'Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid **arthritis** treated with **tocilizumab**' by Pethoe-Schramm et al.

Shafran IH, Alasti F, Smolen JS, Aletaha D.

Ann Rheum Dis. 2020 Jul 31;annrheumdis-2020-218403. doi:

10.1136/annrheumdis-2020-218403. Online ahead of print. Otettu 2.11.20

Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid **arthritis** treated with **tocilizumab**.

Shafran IH, Alasti F, Smolen JS, Aletaha D.

Ann Rheum Dis. 2020 Jul;79(7):874-882. doi: 10.1136/annrheumdis-2019-215987. Epub 2020 May 5.

PMID: 32371387 Otettu 2.11.20

[NeuroBehcet's-related intracranial hypertension without cerebral venous thrombosis: case report and review of literature.](#)

Shah JM, Fong W, De Silva DA.

BMC Neurol. 2024 Jun 14;24(1):203. doi: 10.1186/s12883-024-03708-x.

PMID: 38877431 [Free PMC article](#). Review. Otettu 26.11.24

727.

[Tocilizumab treatment for neuro-Behcet's disease, the first report.](#)

Shapiro LS, Farrell J, Borhani Haghighi A.

Clin Neurol Neurosurg. 2012 Apr;114(3):297-8. doi: 10.1016/j.clineuro.2011.10.024. Epub 2011 Nov 9. No abstract available.

PMID:

22078418

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Efficacy and Safety of **Tocilizumab** in Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis.](#)

Sharma M, Das SK, Mohindra R, Dutta D.

Int J Rheum Dis. 2025 Feb;28(2):e70106. doi: 10.1111/1756-185X.70106.

PMID: 39895497 Review. Otta M

Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents.

Sharp M, Donnelly SC, Moller DR.

Respir Med X. 2019;1:100004. doi: 10.1016/j.ymex.2019.100004. Epub 2019 Feb 21.

PMID: 31187094 **Free PMC article.** Otettu 9.1.21

.

[Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome.](#)

Shendi HM, Devlin LA, Edgar JD.

J Clin Rheumatol. 2014 Mar;20(2):103-5. doi: 10.1097/01.RHU.0000442576.41537.de.

PMID:

24561416

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of **tocilizumab** in systemic sclerosis.

Sheng XR, Gao X, Schiffman C, Jiang J, Ramalingam TR, Lin CJF, Khanna D, Neighbors M.

Clin Immunol. 2023 Sep;254:109695. doi: 10.1016/j.clim.2023.109695. Epub 2023 Jul 20.

PMID: 37479123 **Free article.** Clinical Trial. Otettu 30.8.23

Tocilizumab (Actemra).

Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B.

Hum Vaccin Immunother. 2017 Sep 2;13(9):1972-1988. doi: 10.1080/21645515.2017.1316909.

PMID:

28841363 ei ole M

[Similar articles](#)

217.

Tocilizumab in the treatment of rheumatoid arthritis and beyond.

Shetty A, Hanson R, Korsten P, Shawagfeh M, Arami S, Volkov S, Vila O, Swedler W, Shunaigat AN, Smadi S, Sawaqed R, Perkins D, Shahrara S, Sweiss NJ.

Drug Des Devel Ther. 2014 Mar 28;8:349-64. doi: 10.2147/DDDT.S41437. eCollection 2014.

Review.

PMID:

24729685

[PubMed - indexed for MEDLINE] Otettu 24..7.15

[Free PMC Article](#)

[Related citations](#)

A Giant Silence - An atypical association of sensorineural hearing loss with Giant Cell Arteritis.

Shi YF, Malik S.

Int J Rheum Dis. 2022 Jul 26. doi: 10.1111/1756-185X.14401. Online ahead of print.

PMID: 35880512 Otettu 13.8.22

620.

[Successful treatment with **tocilizumab** in a case of Cogan's syndrome complicated with aortitis.](#)

Shibuya M, Fujio K, Morita K, Harada H, Kanda H, Yamamoto K.

Mod Rheumatol. 2013 May;23(3):577-81. doi: 10.1007/s10165-012-0691-0. Epub 2012 Jul 1.

PMID:

22752533

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody **tocilizumab**.](#)

Shima Y, Kuwahara Y, Kitaba S, Kawai M, Hirano T, Arimitsu J, Narazaki M, Hagihara K, Ogata A, Katayama I, Kawase I, Kishimoto T, Tanaka T.

Rheumatology (Oxford). 2010 Dec;49(12):2408-12. doi: 10.1093/rheumatology/keq275. Epub 2010 Sep 5.

PMID:

20819796

[PubMed - indexed for MEDLINE] [Kokotekstinä](#) Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

[Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis.](#)

Shima Y, Tomita T, Ishii T, Morishima A, Maeda Y, Ogata A, Kishimoto T, Tanaka T.

Mod Rheumatol. 2011 Aug;21(4):436-9. doi: 10.1007/s10165-011-0416-9. Epub 2011 Feb 9.

PMID:

21308388

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis.

Shima Y.

Mod Rheumatol. 2019 Mar;29(2):294-301. doi: 10.1080/14397595.2018.1559909. Epub 2019 Feb 6.

PMID: 30561237 Review. Otettu 9.1.21

[Serum interleukin 6 before and after therapy with **tocilizumab** is a principal biomarker in patients with rheumatoid arthritis.](#)

Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S. J Rheumatol. 2013 Jul;40(7):1074-81. doi: 10.3899/jrheum.121389. Epub 2013 May 1.

PMID:

23637318

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Expansion of range of joint motion following treatment of systemic sclerosis with **tocilizumab**.](#)

Shima Y, Hosen N, Hirano T, Arimitsu J, Nishida S, Hagihara K, Narazaki M, Ogata A, Tanaka T, Kishimoto T, Kumanogoh A.

Mod Rheumatol. 2015 Jan;25(1):134-7. doi: 10.3109/14397595.2013.874749. Epub 2014 Feb 18.

PMID:

24533556

[PubMed - in process] ei ole M

[Related citations](#)

Add-on **tocilizumab** (TCZ) versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to TCZ therapy.

Shima Y, Kawaguchi Y, Kuwana M.

Mod Rheumatol. 2018 Mar 13;1-16. doi: 10.1080/14397595.2018.1452178. [Epub ahead of print]

PMID:

29529897 ei ole M

[Similar articles](#)

Successful treatment with **tocilizumab** for massive ascites due to secondary amyloidosis complicating rheumatoid **arthritis**: a case report.

Shimagami H, Katada Y.

Scand J Rheumatol. 2019 Nov;48(6):511-512. doi: 10.1080/03009742.2019.1603325. Epub 2019 Jun 27.

PMID: 31244353 No abstract available. Otta M

Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6.

Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, Yachie A.

Cytokine. 2012 May;58(2):287-94. doi: 10.1016/j.cyto.2012.02.006. Epub 2012 Mar 6.

PMID:

22398373

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

Select item 22397953678.

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and **tocilizumab** examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial.

Shimizu T, Kawashiri SY, Morimoto S, Kawazoe Y, Kuroda S, Kawasaki R, Ito Y, Kiya R, Sato S, Yamamoto H, Kawakami A.

Trials. 2023 Mar 3;24(1):161. doi: 10.1186/s13063-023-07176-5.

PMID: 36869356 [Free PMC article](#). [Otettu 4.6.23](#)

[Relapse of systemic juvenile idiopathic arthritis after influenza vaccination in a patient receiving **tocilizumab**.](#)

Shimizu M, Ueno K, Yachie A.

Clin Vaccine Immunol. 2012 Oct;19(10):1700-2. Epub 2012 Aug 8.

PMID:

22875602

[PubMed - indexed for MEDLINE] [Otettu 24.7.15](#)

[Free PMC Article](#)

[Related citations](#)

[Successful treatment with **tocilizumab** of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis.](#)

Shimizu M, Hamaguchi Y, Ishikawa S, Ueno K, Yachie A.
Mod Rheumatol. 2014 Dec 15:1-2. [Epub ahead of print] No abstract available.

PMID:

25496406

[PubMed - as supplied by publisher] Ei ole M

[Related citations](#)

[Successful treatment with **tocilizumab** for refractory scleritis associated with relapsing polychondritis.](#)

Shimizu H, Nishioka H.

Scand J Rheumatol. 2017 Sep;46(5):418-419. doi: 10.1080/03009742.2016.1275774. Epub 2017 Jan 25. No abstract available.

PMID: Otettu 2.5.2018

28120637

[Similar articles](#)

Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic **arthritis**.

Shimizu M, Mizuta M, Okamoto N, Yasumi T, Iwata N, Umebayashi H, Okura Y, Kinjo N,, Nakagishi Y, Nishimura K, Mohri M, Yashiro M, Yasumura J, Wakiguchi H, Mori M.

Pediatr Rheumatol Online J. 2020 Jan 10;18(1):2. doi: 10.1186/s12969-020-0399-1.
PMID: 31924225 [Free PMC article](#). [Otettu 2.11.20](#)

[Analysis of Early EEG Changes After **Tocilizumab** Treatment in New-Onset Refractory Status Epilepticus.](#)

Shin YW, Hong SB, Lee SK.

Brain Sci. 2025 Jun 13;15(6):638. doi: 10.3390/brainsci15060638.

PMID: 40563808 [Free PMC article](#). [Ota](#)

[Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving **tocilizumab**.](#)

Shinoki T, Hara R, Kaneko U, Miyamae T, Imagawa T, Mori M,

Mod Rheumatol. 2012 Nov;22(6):871-6. doi: 10.1007/s10165-012-0595-z. Epub 2012 Feb 11.

PMID:

22322589

[PubMed - indexed for MEDLINE] [Otettu 3.6.15](#)

[Related citations](#)

1023.

[Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.](#)

Shinriki S, Jono H,, Ueda M, Kudo M,, Oike Y, Endo M, Ibusuki M, Hiraki A, Nakayama H, Yoshitake Y, Shinohara M, Ando Y.

Clin Cancer Res. 2009 Sep 1;15(17):5426-34. doi: 10.1158/1078-0432.CCR-09-0287. Epub 2009 Aug 25.

PMID:

19706815

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

[Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma.](#)

Shinriki S, Jono H, Ueda M,,, Sueyoshi T, Oike Y, Ibusuki M, Hiraki A, Nakayama H, Shinohara M, Ando Y.

J Pathol. 2011 Sep;225(1):142-50. doi: 10.1002/path.2935. Epub 2011 Jun 25.

PMID:

21710490

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Rheumatoid arthritis: **Tocilizumab** and the risk of intestinal perforation.](#)

Shipman L.

Nat Rev Rheumatol. 2016 Sep;12(9):499. doi: 10.1038/nrrheum.2016.130. Epub 2016 Jul 28. No abstract available.

PMID: Otettu 2.5.2018

27464481

[Similar articles](#)

[Vasculitis syndromes: **Tocilizumab** safe and effective for PMR.](#)

Shipman L.

Nat Rev Rheumatol. 2016 Jul;12(7):374. doi: 10.1038/nrrheum.2016.89. Epub 2016 May 26. No abstract available.

PMID: Otettu 4.5.18

27225306

[Similar articles](#)

[Active withdrawal of corticosteroids using **tocilizumab** and its association with autoantibody profiles in relapsed Takayasu arteritis: a multicentre, single-arm, prospective study \(the Ab-TAK study\).](#)

Shirai T, Ishii T, Okazaki S, Ishii Y, Sato H, Fujii H.

Front Immunol. 2025 Jan 7;15:1473100. doi: 10.3389/fimmu.2024.1473100. eCollection 2024.

PMID: 39840060 [Free PMC article](#). Otettu 14.2.25

[TAFRO syndrome is associated with anti-SSA/Ro60 antibodies, in contrast to idiopathic castleman disease.](#)

Shirakashi M, Nishida Y, Nakashima R, Fujimoto M, Hiwa R, Tsuji H, Kitagori K, Akizuki S, Morinobu A, Yoshifuji H.

Sci Rep. 2024 Feb 5;14(1):2889. doi: 10.1038/s41598-024-53413-5.

PMID: 38311632 [Free PMC article](#). Otettu 7.3.24

228.

[Multidisciplinary approach to the treatment of cardiac AA amyloidosis and aortic stenosis due to Castleman's disease: a hybrid therapy with **tocilizumab** and aortic valve replacement.](#)

Shirakawa K, Egashira T, Ieda M, Kawaguchi S, Okamoto K, Kudo M, Yokoyama K, Tsuruta H, Murata M, Mikami S, Anzai A, Hayashida K, Kohno T, Maekawa Y, Sano M, Yozu R, Fukuda K.

Int J Cardiol. 2014 May 1;173(2):e9-e11. doi: 10.1016/j.ijcard.2014.03.054. Epub 2014 Mar 16.
No abstract available.

PMID:

24681024

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus.](#)

, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG.

Ann Rheum Dis. 2013 Jan;72(1):118-28. doi: 10.1136/annrheumdis-2012-201310. Epub 2012 Aug 2.

PMID:

22858586

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Cutaneous sarcoidosis in a patient with rheumatoid arthritis receiving tocilizumab.](#)

Shono Y, Kamata M, Takeoka S, Ikawa T, Tateishi M, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Ohnishi T, Asako K, Kono H, Tada Y.

J Dermatol. 2018 Mar 3. doi: 10.1111/1346-8138.14268. [Epub ahead of print] No abstract available.

PMID:

29500868 Otettu 2.5.2018

[Similar articles](#)

74.

[Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature.](#)

Shovman O, Shoenfeld Y, Langevitz P.

Immunol Res. 2015 Feb;61(1-2):164-8. doi: 10.1007/s12026-014-8590-4.

PMID:

25403696

[PubMed - in process] Ei ole M

[Related citations](#)

[Risk Factors and Pharmacological Interventions Impacting Cerebrovascular Ischemic Events in Giant Cell Arteritis: A Narrative Review.](#)

Siddiqui MO, Syed MA, Qureshi AA, Imam MH, Motwani J, Kumari V, Siddiqui A, Ul Ain N, Jaber MH.

Immun Inflamm Dis. 2025 Jan;13(1):e70122. doi: 10.1002/iid3.70122.

PMID: 39817601 [Free PMC article](#). Review. Otettu 14.2.25

[New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025.](#)

Sieiro Santos C, Del Galdo F.

RMD Open. 2025 Jul 1;11(3):e005776. doi: 10.1136/rmdopen-2025-005776.

PMID: 40592721 [Free PMC article](#). Review. Ota

[Assessment of short-term symptomatic efficacy of **tocilizumab** in ankylosing spondylitis: results of randomised, placebo-controlled trials.](#)

Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M.

Ann Rheum Dis. 2014 Jan;73(1):95-100. doi: 10.1136/annrheumdis-2013-203559. Epub 2013 Jun 13.

PMID:

23765873

[PubMed - indexed for MEDLINE] [Kokotekstinä](#) Otettu 25.7.15

[Free PMC Article](#)

[Related citations](#)

[Immunogenicity of **tocilizumab** in patients with rheumatoid arthritis.](#)

Sigaux J, Hamze M, Daien C, Morel J, Krzysiek R, Pallardy M, Maillere B, Mariette X, Miceli-Richard C.

Joint Bone Spine. 2017 Jan;84(1):39-45. doi: 10.1016/j.jbspin.2016.04.013. Epub 2016 Jun 28.

PMID: Otettu 2.5.2018

27369643

[Similar articles](#)

[Intestinal disease secondary to **tocilizumab**.](#)

Siljeström Berenguer C, Bonilla G, Suárez-Ferrer C.

Rev Esp Enferm Dig. 2022 Jun 3. doi: 10.17235/reed.2022.8818/2022. Online ahead of print.

PMID: 35656897 [Free article.](#) Otettu 16.7.22

Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous **tocilizumab**.
Silkiss RZ, Paap MK, Roelofs KA, Agi J, Weis E.
Can J Ophthalmol. 2020 Sep 10:S0008-4182(20)30706-7. doi: 10.1016/j.jcjo.2020.07.020.
Online ahead of print. Otta M

Outcome of **tocilizumab** treatment in refractory ocular inflammatory diseases.

Silpa-Archa S, Oray M, Preble JM, Foster CS.
Acta Ophthalmol. 2016 Sep;94(6):e400-6. doi: 10.1111/aos.13015. Epub 2016 Mar 24.
Otettu 22.9.18

27010181

Free Article

[Similar articles](#)

Tocilizumab-induced pulmonary fibrosis in a patient with rheumatoid **arthritis**.
Silva S, Amarasena R, Moorcroft J, Rajakulenthiran T, Singh R.
Clin Med (Lond). 2020 Mar;20(Suppl 2):s57. doi: 10.7861/clinmed.20-2-s57.
PMID: 32409376 **Free PMC article.** Otettu 2.11.20

Influenza-Associated Acute Necrotizing Encephalopathy in US Children.

Influenza-Associated Acute Necrotizing Encephalopathy (IA-ANE) Working Group; Silverman A, Walsh R, Santoro JD, Thomas K, Ballinger E, Fisher KS, Thomas AX, Appavu B, Kruer MC, Neilson D, Knoll J, Sharp AN, Edelman HE, Otallah S, Morgan A, Grzezulkowska A, Nguyen J, Rao LM, Hecht SM, Catalano L, Daigle H, Kronfol C, Wharton J, Adams D, Kalawi AZ, Kung M, Arellano JL, Smith L, Segal D, Feja K, Broomall E, Jayakar A, Arnold SR, Retallack H, Press CA, Gombolay G, McLaughlin MH, Kannan V, Thakkar K, Rezwan T, Hulfish E, Eid D, Meylor J, Peng D, Hurtado R, Nickerson T, Mandell I, Carbonell AU, Kerner-Rossi M, Jayaraman D, Davis M, Olivero R, Shah N, Osborne CM, Zhang B, Cortina C, Randolph AG, Rao S, LaRocca T, Van Haren KP, Wilson-Murphy M. *JAMA*. 2025 Jul 30:e2511534. doi: 10.1001/jama.2025.11534. Online ahead of print. PMID: 40736730 Ota

Rheumatoid **arthritis** treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis. Simpson EL, Ren S, Hock ES, Stevens JW, Binard A, Pers YM, Archer R, Paisley S, Stevenson MD, Herpin C, Ghabri S. *Int J Technol Assess Health Care*. 2019 Jan;35(1):36-44. doi: 10.1017/S0266462318003628. Epub 2019 Feb 6. PMID: 30722803 Free article. Otta M

Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management. Singh S, Tiwary N, Sharma N, Behl T, Antil A, Anwer MK, Ramniwas S, Sachdeva M, Elossaily GM, Gulati M, Ohja S. *Pharmaceuticals (Basel)*. 2024 Feb 14;17(2):248. doi: 10.3390/ph17020248. PMID: 38399463 Free PMC article. Review. Otettu 17.4.24

[Clinical efficacy and safety evaluation of drug therapies for the treatment of progressive fibrotic-interstitial lung diseases \(PF-ILDs\): a network meta-analysis of randomized controlled trials.](#)

Singh P, Thampi G, Gupta K, Gangte N, Pattnaik B, Agrawal A, Kukreti R.

Expert Rev Clin Immunol. 2025 Aug 3. doi: 10.1080/1744666X.2025.2543473. Online ahead of print.

PMID: 40754799 Review. Ota

[Tocilizumab for rheumatoid arthritis.](#)

Singh JA, Beg S, Lopez-Olivo MA.

Cochrane Database Syst Rev. 2010 Jul 7;(7):CD008331. doi:

10.1002/14651858.CD008331.pub2. Review.

PMID:

20614469

[PubMed - indexed for MEDLINE] ei ole M

[Related citations](#)

904.

[Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.](#)

Singh JA, Beg S, Lopez-Olivo MA.

J Rheumatol. 2011 Jan;38(1):10-20. doi: 10.3899/jrheum.100717. Epub 2010 Oct 15. Review.

PMID:

20952462

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Cat-scratch fever and lymphadenopathy in a rheumatoid arthritis patient on **tocilizumab**.](#)

Singh N, Sinclair LL, IJdo J.

J Clin Rheumatol. 2015 Jan;21(1):40. doi: 10.1097/RHU.0000000000000203. No abstract available. **OK**

PMID:

25539435

[PubMed - in process] Otettu 3.6.2015

[Related citations](#)

Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid **Arthritis**: A Systematic Review and Meta-Analysis.

Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, Sandborn WJ, Curtis JR.

Arthritis Care Res (Hoboken). 2020 Apr;72(4):561-576. doi: 10.1002/acr.23875.

PMID: 30875456 **Free PMC article.** Otettu 2.11.20

Efficacy and safety of **tocilizumab** in treatment of Takayasu arteritis: A systematic review of randomized controlled trials.

Singh A, Danda D, Hussain S, Najmi AK, Mathew A, Goel R, Lakhan SE, Tajudheen B, Antony B.

Mod Rheumatol. 2021 Jan;31(1):197-204. doi: 10.1080/14397595.2020.1724671. Epub 2020 Feb 13.

PMID: 32000551 Otta M

[A child with systemic onset juvenile idiopathic arthritis and nephrotic syndrome.](#)

Singhal JS, Pande N, Sharma J.

Pediatr Nephrol. 2024 Sep 9. doi: 10.1007/s00467-024-06495-2. Online ahead of print.

PMID: 39249127 Otta M

Tocilizumab Beneficial for Adults With Persistent Polymyalgia Rheumatica Symptoms Who Receive Steroid Therapy.

Slawson DC.

Am Fam Physician. 2023 Mar;107(3):317-318.

PMID: 36920801 Otta M

This Month in JAAD Case Reports: March 2023: **Tocilizumab** for refractory morphea.

Sloan SB.

J Am Acad Dermatol. 2023 Mar;88(3):547. doi: 10.1016/j.jaad.2022.12.028. Epub 2022 Dec 29.

PMID: 36586486 Otta M

Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.

Smith TJ.

J Clin Endocrinol Metab. 2022 Aug 8;107(Suppl_1):S13-S26. doi: 10.1210/clinem/dgac328.

PMID: 36346686 **Free PMC article.** Otettu 4.6.23

Tocilizumab for the Management of Thyroid-Associated Orbitopathy.

Smith LD, Moscato EE, Seiff SR.

Ophthalmic Plast Reconstr Surg. 2021 Jul 21. doi: 10.1097/IOP.0000000000002027. Online ahead of print.

PMID: 34293786 Otettu 6.8.21

1173.

[Interleukin-6: a new therapeutic target.](#)

Smolen JS, Maini RN.

Arthritis Res Ther. 2006;8 Suppl 2:S5. Epub 2006 Jul 28. Review. Erratum in: Arthritis Res Ther. 2006;8(6):407.

PMID:

16899109

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

Efficacy and safety of CT-P47 versus reference **tocilizumab**: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference **tocilizumab** to CT-P47.

Smolen JS, Trefler J, Racewicz A, Jaworski J, Zielińska A, Krogulec M, Jeka S, Wojciechowski R, Kolossa K, Dudek A, Krajewska-Włodarczyk M, Hrycaj P, Klimiuk PA, Burmester GR, Kim S, Bae Y, Yang G, Jung Y, Hong J, Keystone E.

RMD Open. 2024 Oct 18;10(4):e004514. doi: 10.1136/rmdopen-2024-004514.

PMID: 39424404 [Free PMC article](#). Clinical Trial. Otettu 26.11.24

1123.

[Effect of interleukin-6 receptor inhibition with **tocilizumab** in patients with rheumatoid arthritis \(OPTION study\): a double-blind, placebo-controlled, randomised trial.](#)

Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators.

Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5.

PMID:

18358926

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[Interleukin-6 receptor inhibition with **tocilizumab** and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.](#)

Smolen JS, Aletaha D.

Arthritis Rheum. 2011 Jan;63(1):43-52. doi: 10.1002/art.27740.

PMID:

21204103

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

Select item 22693300875.

[Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.](#)

Smolen JS, Avila JC, Aletaha D.

Ann Rheum Dis. 2012 May;71(5):687-93. doi: 10.1136/annrheumdis-2011-200395. Epub 2011 Nov 25.

PMID:

22121130

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.](#)

Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D.

Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10.

PMID: 36357155 Otettu 4.6.23

[Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.](#)

Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanås A, Martín-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D. Ann Rheum Dis. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21.

PMID:

23172750

[PubMed - indexed for MEDLINE] [Kokotekstinä](#) Otettu 25.7.15

[Free PMC Article](#)

[Related citations](#)

361.

[Proposal for a new nomenclature of disease-modifying antirheumatic drugs.](#)

Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R.

Ann Rheum Dis. 2014 Jan;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317. Epub 2013 Sep 26.

PMID:

24072562

[PubMed - indexed for MEDLINE] Otettu 3.6.15

[Related citations](#)

[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.](#)

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgerit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D.

Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25.

PMID:

24161836

[PubMed - indexed for MEDLINE] [Kokotekstinä](#) Otettu 25.7.15

[Free PMC Article](#)

[Related citations](#)

EULAR recommendations for the management of rheumatoid **arthritis** with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruysen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D.

Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.

PMID: 31969328 [Free article.](#) Otettu 2.11.20

[Failure of tocilizumab treatment in a CINCA patient: clinical and pathogenic implications.](#)

Snegireva LS, Kostik MM, Caroli F, Ceccherini I, Gattorno M, Chasnyk VG.

Rheumatology (Oxford). 2013 Sep;52(9):1731-2. doi: 10.1093/rheumatology/ket121. Epub 2013 Mar 12. No abstract available.

PMID:

23481539

[PubMed - indexed for MEDLINE] Otettu 3.6.15 Ei oteta

[Related citations](#)

789.

[Anti-IL-6 receptor antibody \(tocilizumab\): a B cell targeting therapy.](#)

Snir A, Kessel A, Haj T, Rosner I, Slobodin G, Toubi E.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):697-700. Epub 2011 Sep 1.

PMID:

21813064

[PubMed - indexed for MEDLINE] Otettu 5.4.18

[Related citations](#)

Drug Persistence and Incidence of Active Tuberculosis of Tumor Necrosis Factor Alpha Inhibitors Versus **Tocilizumab** as the First-Line Biological Treatment in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Retrospective Cohort Analysis.

So MW, Kim AR, Lee SG.

Rheumatol Ther. 2024 Aug;11(4):881-895. doi: 10.1007/s40744-024-00674-1. Epub 2024 May 20.

PMID: 38769252 [Free PMC article.](#) Otettu 26.11.24

The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of **tocilizumab** monotherapy.

Solomon DH, Xu C, Collins J, Kim SC, Losina E, Yau V, Johansson FD.

Arthritis Res Ther. 2021 Jan 14;23(1):26. doi: 10.1186/s13075-020-02408-4.

PMID: 33446261 [Free PMC article.](#) Otettu 6.8.21

Comprehensive Physico-Chemical and Functional Similarity Assessment of Intravenous and Subcutaneous RGB-19 Drug Products as Proposed Biosimilars to **Tocilizumab** Reference Product.

Solti K, Timári S, Faludi T, Iliás A, Hegedüs R, Pataj Z, Háda V.

BioDrugs. 2025 Aug 1. doi: 10.1007/s40259-025-00734-0. Online ahead of print.

PMID: 40751115 Ota

[Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody \(**tocilizumab**\) improves anemia of inflammation in multicentric Castleman disease.](#)

Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K.

Blood. 2010 Nov 4;116(18):3627-34. doi: 10.1182/blood-2010-03-271791. Epub 2010 Jul 19.

PMID:

20644113

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

[Comparative evaluation of the effects of treatment with **tocilizumab** and TNF- \$\alpha\$ inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients.](#)

Song SN, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S, Isobe T, Ito H, Kawabata H, Yoshizaki K.

Arthritis Res Ther. 2013 Oct 2;15(5):R141. doi: 10.1186/ar4323.

PMID:

24286116

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

61.

[Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.](#)

Song SN, Yoshizaki K.

Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):307-16. doi: 10.1517/17425255.2015.992779.

Epub 2014 Dec 10.

PMID:

25491492

[PubMed - in process] ei ole M

[Related citations](#)

Efficacy of **tocilizumab** therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases.

Song ST, Kim JJ, Lee S, Kim HA, Lee EY, Shin KC, Lee JH, Lee KH, Choi ST, Cha HS, Yoo DH.

Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):S64-S71. Epub 2016 Jul 26.

PMID:

27462914 Otettu 5.4.18

[Similar articles](#)

Efficacy and safety of biological agents in patients with giant cell arteritis: A meta-analysis of randomized trials.

Song GG, Lee YH.

Int J Clin Pharmacol Ther. 2020 Sep;58(9):504-510. doi: 10.5414/CP203738.

PMID: 32567545 Otta M

Giant Aortic Aneurysm in Refractory Behcet's Disease Shrank with **Tocilizumab** Treatment: A Case Report.

Song ZY, Zhi X, Geng JY, Sun X, Liu T, Li ZG.

ACR Open Rheumatol. 2025 Jul;7(7):e70071. doi: 10.1002/acr2.70071.

PMID: 40609976 **Free PMC article.** Ota

Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With **Tocilizumab**.

Sonneveld MJ, Murad SD, van der Eijk AA, de Man RA.

ACG Case Rep J. 2019 Dec 9;6(12):e00243. doi: 10.14309/crj.0000000000000243. eCollection 2019 Dec.

PMID: 32042838 [Free PMC article](#). Otettu 2.11.20

Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review.

, Girolamo MM, Frediani B, Tosi GM, Cantarini L, Fabiani C.

Ophthalmol Ther. 2021 Dec;10(4):777-813. doi: 10.1007/s40123-021-00393-8. Epub 2021 Sep 2.

PMID: 34476773 [Free PMC article](#). Otettu 16.7.22

Efficacy and safety of **tocilizumab** in adult-onset Still's disease: Real-life experience from the international AIDA registry.

Sot J, et al. Semin Arthritis Rheum. 2022. PMID: 36063578 Otta M

Therapeutic approach to central nervous system involvement of Behçet's disease.

Sot J, Capuano A, Emmi G, Iannone F, Cantarini L, Hatemi G, Lopalco G.

Semin Arthritis Rheum. 2023 Apr 26;61:152206. doi: 10.1016/j.semarthrit.2023.152206. Online ahead of print.

PMID: 37172497 Review. Otta M

Efficacy and safety of **tocilizumab** in adult-onset Still's disease: Real-life experience from the international AIDA registry.

Sot J, Vitale A, Lopalco G, Pereira RMR, Giordano HF, Antonelli IPB, Makowska J, Brzezińska O, Lewandowska-Polak A, Ruscitti P, Cipriani P, Cola ID, Govoni M, Ruffili F, Sfrikakis PP, Laskari K, Ragab G, Hussein MA, Gentileschi S, Gaggiano C, La Torre F, Maier A, Emmi G, Marino A, Ciccio F, Sfriso P, Maggio MC, Bartoloni E, Lomater C, Hegazy MT, Tektonidou M, Dagostin MA, Opinc A, Sebastiani GD, Giacomelli R, Giudice ED, Olivieri AN, Tufan A, Kardas RK, Nuzzolese R, Cardinale F, Więsik-Szewczyk E, Veronica P, Tarsia M, Iannone F, Della Casa F, Fabiani C, Frediani B, Balistreri A, Rigante D, Cantarini L.

Semin Arthritis Rheum. 2022 Dec;57:152089. doi: 10.1016/j.semarthrit.2022.152089. Epub 2022 Aug 30.

PMID: 36063578 Otta M

Concomitant Use of Statins in **Tocilizumab**-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis.

Soubrier M, Pei J, Durand F, Gullestad L, John A.

Rheumatol Ther. 2017 Jun;4(1):133-149. doi: 10.1007/s40744-016-0049-8. Epub 2016 Nov 29.

PMID:

27900570 Otettu 5.4.18

Free PMC Article

Similar articles

[Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody \(tocilizumab\).](#)

Souri M, Mokuda S, Inanami H, Osaki T, Takasugi K, Ichinose A.

Thromb Res. 2016 Apr;140:100-105. doi: 10.1016/j.thromres.2016.02.026. Epub 2016 Feb 26.

PMID: Otettu 4.5.18

26938156

[Similar articles](#)

Tocilizumab in refractory juvenile idiopathic **arthritis** with associated uveitis: a case report.

Sousa-Neves F, Braga J, Teixeira S, Barge S, Fonseca S, Meira D, Rodrigues L, Varandas R.

Acta Reumatol Port. 2019 Apr-Jun;44(2):151-154.

PMID: 31455751 **Free article**. English. Otettu 2.11.20

IL-6-targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function.

Speake C, Habib T, Lambert K, Hundhausen C, Lord S, Dufort MJ, Skinner SO, Hu A, Kinsman M, Jones BE, Maerz MD, Tatum M, Hocking AM, Nepom GT, Greenbaum CJ, Buckner JH.

JCI Insight. 2022 Nov 22;7(22):e159436. doi: 10.1172/jci.insight.159436.

PMID: 36282595 [Free PMC article.](#) Otettu 3.6.23

ICHIBAN, a non-interventional study evaluating **tocilizumab** long-term effectiveness and safety in patients with active rheumatoid **arthritis**.

Specker C, Alberding A, Aringer M, Burmester GR, Flacke JP, Hofmann MW, Kästner P, Kellner H, Moosig F, Sieburg M, Tony HP, Fliedner G.

Clin Exp Rheumatol. 2020 Jul 10. Online ahead of print.

PMID: 32662413 Otettu 9.1.21

The safety and effectiveness of **tocilizumab** in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age.

Specker C, Aringer M, Burmester GR, Killy B, Hofmann MW, Kellner H, Moosig F, Tony HP, Fliedner G.

Clin Exp Rheumatol. 2021 Nov 22. Online ahead of print.

PMID: 34874836 Otettu 16.7.22

Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.

Spiera R, Unizony SH, Bao M, Luder Y, Han J, Pavlov A, Stone JH.

Semin Arthritis Rheum. 2021 Apr;51(2):469-476. doi: 10.1016/j.semarthrit.2021.03.006. Epub 2021 Mar 18.

PMID: 33784598 [Free article.](#) Otettu 6.8.21

[The role of interleukin 6 in the pathophysiology of rheumatoid arthritis.](#)

Srirangan S, Choy EH.

Ther Adv Musculoskelet Dis. 2010 Oct;2(5):247-56. doi: 10.1177/1759720X10378372.

PMID:

22870451 Otettu 24.7.15

[PubMed]

[Free PMC Article](#)

[Related citations](#)

[Sustained response to **tocilizumab** in a patient with relapsing polychondritis with aortic involvement: a case based review.](#)

Stael R, Smith V, Wittoek R, Creytens D, Mielants H.

Clin Rheumatol. 2015 Jan;34(1):189-93. doi: 10.1007/s10067-014-2670-7. Epub 2014 May 16.

PMID:

24831688

[PubMed - in process] Otettu 2.5.2018

[Related citations](#)

Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients - the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response - results from the multicenter observational ACT-POL study.

Stajszczyk M, Jeka S, Juś A, Pawlak-Buś K.

Reumatologia. 2022;60(2):92-100. doi: 10.5114/reum.2022.115986. Epub 2022 May 18.

PMID: 35782029 [Free PMC article.](#) Otettu 16.7.22

[What Is New in Morphea-Narrative Review on Molecular Aspects and New Targeted Therapies.](#)

Stein T, Cieplewicz-Guźla P, Iżykowska K, Pieniawska M, Żaba R, Dańczak-Pazdrowska A, Polańska A.

J Clin Med. 2024 Nov 25;13(23):7134. doi: 10.3390/jcm13237134.

PMID: 39685593 [Free PMC article](#). Review. Otettu 14.2.25

[Impaired lymphatic function accelerates cancer growth.](#)

Steinskog ES, Sagstad SJ, Wagner M, Karlsen TV, Yang N, Markhus CE, Yndestad S, Wiig H, Eikesdal HP.

Oncotarget. 2016 Jul 19;7(29):45789-45802. doi: 10.18632/oncotarget.9953.

PMID: Otettu 5.4.18

27329584

[Free PMC Article](#)

[Similar articles](#)

[Riesenzellarteriitis: **Tocilizumab** zusätzlich zu Prednison steigert die Rate länger anhaltender Remissionen.](#)

Steurer J.

Praxis (Bern 1994). 2017;106(22):1251-1252. doi: 10.1024/1661-8157/a002823. German. No abstract available.

PMID:

29088969 Otettu 2.5.2018

[Similar articles](#)

128.

[TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome.](#)

Stoffels M, Jongekrijg J, Remijn T, Kok N, van der Meer JW, Simon A.

Rheumatology (Oxford). 2015 Feb;54(2):363-8. doi: 10.1093/rheumatology/keu341. Epub 2014 Aug 29.

PMID:

25173351

[PubMed - in process] Otettu 4.5.18

[Related citations](#)

[Trial of Tocilizumab in Giant-Cell Arteritis.](#)

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N.

N Engl J Med. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849.

PMID:

28745999 Otettu 5.4.18

[Free Article](#)

[Similar articles](#)

New-onset versus relapsing giant cell arteritis treated with **tocilizumab**: 3-year results from a randomized controlled trial and extension.

Stone JH, Spotswood H, Unizony SH, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M.

Rheumatology (Oxford). 2021 Oct 29;keab780. doi: 10.1093/rheumatology/keab780. Online ahead of print.

PMID: 34718434 Otettu 16.7.22

Trial of **Tocilizumab** in Giant-Cell Arteritis.

Stone JH, Klearman M, Collinson N.

N Engl J Med. 2017 Oct 12;377(15):1494-1495. doi: 10.1056/NEJMc1711031. No abstract available.

PMID:

29020600 Otettu 4.5.18

[Similar articles](#)

Foreword: clinical challenges of diagnosing and managing giant cell arteritis.

Stone JH.

Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii1-ii2. doi: 10.1093/rheumatology/key003.

PMID: 29982783 Otettu 6.8.21

Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of **Tocilizumab**.

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony SH, Collinson N. Arthritis Rheumatol. 2019 Aug;71(8):1329-1338. doi: 10.1002/art.40876. Epub 2019 Jul 3. PMID: 30835950 [Free PMC article](#). Clinical Trial. Otettu 2.11.20

[A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: A case report.](#)

Strach M, Kuzmiersz P, Chmura Ł, Korkosz M.

Clin Case Rep. 2023 Oct 17;11(10):e7981. doi: 10.1002/ccr3.7981. eCollection 2023 Oct.

PMID: 37854256 [Free PMC article](#). Otettu 7.3.24

1138.

[Interleukin-6 inhibition--tolerability profile and clinical implications.](#)

Strand V, Yazici Y.

Bull NYU Hosp Jt Dis. 2007;65 Suppl 1:S21-4. Review.

PMID:

17708741

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free Article](#)

[Related citations](#)

Select item 177087401139.

[Improvements in health-related quality of life after treatment with **tocilizumab** in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study.](#)

Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P.
Rheumatology (Oxford). 2012 Oct;51(10):1860-9. Epub 2012 Jun 28.

PMID:

22753773

[PubMed - indexed for MEDLINE] Otettu 24.7.15

[Free PMC Article](#)

[Related citations](#)

[Impact of **tocilizumab** monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.](#)

Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Gabay C, Kavanaugh A, Jones G.

RMD Open. 2017 Sep 14;3(2):e000496. doi: 10.1136/rmdopen-2017-000496. eCollection 2017.

PMID:

28955499 Otettu 5.4.18

[Free PMC Article](#)

[Similar articles](#)

[Health-related quality of life in patients with giant cell arteritis treated with **tocilizumab** in a phase 3 randomised controlled trial.](#)

Strand V, Dimonaco S, Tuckwell K, Klearman M, Collinson N, Stone JH.
Arthritis Res Ther. 2019 Feb 20;21(1):64. doi: 10.1186/s13075-019-1837-7.

PMID: 30786937 [Free PMC article](#). Clinical Trial. Otettu 2.11.20

[Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by **tocilizumab** in rheumatoid arthritis.](#)

Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, Dallinga-Thie GM, Levels JH, Kok M, Vos K, Tas SW, Tietge UJ, Müller N, Laudes M, Gerlag DM, Stroes ES, Tak PP. Atherosclerosis. 2013 Jul;229(1):174-81. doi: 10.1016/j.atherosclerosis.2013.04.031. Epub 2013 May 11.

PMID:

23746537

[PubMed - indexed for MEDLINE] Otettu 4.5.18

[Related citations](#)

[Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with **tocilizumab** in comparison to treatment with other biologic or conventional synthetic DMARDs.](#)

Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, Aringer M, Meißner Y, Zink A, Listing J.

Ann Rheum Dis. 2017 Mar;76(3):504-510. doi: 10.1136/annrheumdis-2016-209773. Epub 2016 Jul 12.

PMID: Otettu 5.4.18

27405509

Free PMC Article

[Similar articles](#)

[Interleukin-6 Blockade With **Tocilizumab** in Anakinra-Refractory Febrile Infection-Related Epilepsy **Syndrome** \(FIRES\).](#)

Stredny CM, Case S, Sansevere AJ, Son M, Henderson L, Gorman MP.

Child Neurol Open. 2020 Dec 15;7:2329048X20979253. doi: 10.1177/2329048X20979253. eCollection 2020 Jan-Dec.

PMID: 33403221 [Free PMC article.](#) Otettu 6.8.21

The Role of **Tocilizumab** in Glucocorticoid Resistant Giant Cell Arteritis: A Case Series and Literature Review.

Stretton B, Tan Y, Hassall M, Simon S.

J Neuroophthalmol. 2023 Mar 1;43(1):91-95. doi: 10.1097/WNO.0000000000001645. Epub 2022 Oct 5.

PMID: 36166708 Review. Otta M

Tocilizumab: A Role for Biomarker-Directed Therapy?

Strich JR, Chertow DS.

Crit Care Med. 2022 Mar 1;50(3):510-513. doi: 10.1097/CCM.0000000000005281.

PMID: 35191872 Otta M

[Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-**tocilizumab** antibodies with control by surrogate standards.](#)

Stubenrauch K, Wessels U, Vogel R, Schleyen J.

Anal Biochem. 2009 Jul 15;390(2):189-96. doi: 10.1016/j.ab.2009.04.021. Epub 2009 Apr 18.

PMID:

19379704

[PubMed - indexed for MEDLINE] Otettu 4.5.18

[Related citations](#)

[Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the clinical trials of **tocilizumab** for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.](#)

Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleyden J.
Clin Ther. 2010 Aug;32(9):1597-609. doi: 10.1016/j.clinthera.2010.07.021.

PMID:

20974317

[PubMed - indexed for MEDLINE] Otettu 4.5.18

[Related citations](#)

[Successful treatment with **tocilizumab** for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castelman disease: A case report.](#)

Sugawara E, Sato T, Amasaki Y, Katsumata K.

Medicine (Baltimore). 2022 Feb 25;101(8):e28941. doi: 10.1097/MD.00000000000028941.

PMID: 35212301 [Free PMC article.](#) Otettu 16.7.22

[Interstitial lung disease occurring shortly after **tocilizumab** infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report.](#)

Sugihara K, Wakiya R, Shimada H, Kato M, Kameda T, Nakashima S, Mansour MMF, Ushio Y, Kadowaki N, Dobashi H.

Allergy Asthma Clin Immunol. 2021 Sep 8;17(1):90. doi: 10.1186/s13223-021-00594-7.

PMID: 34496961 [Free PMC article.](#) Otettu 16.7.22

[Significant response to **tocilizumab** in a case of immune deposits-related membranoproliferative glomerulonephritis and tubulointerstitial nephritis complicated by multicentric Castleman's disease.](#)

Sugimoto H, Sawa N, Ikuma D, Oba Y, Mizuno H, Sekine A, Yamanouchi M, Hasegawa E, Suwabe T, Wada T, Kono K, Kinowaki K, Ohashi K, Honda K, Kanetsuna Y, Joh K, Yamaguchi Y, Ubara Y. Clin Nephrol Case Stud. 2024 Dec 20;12:73-82. doi: 10.5414/CNCS111337. eCollection 2024. PMID: 39776937 [Free PMC article.](#) Otettu 14.2.25

Tocilizumab Treatment for Takayasu Arteritis in Pregnancy: A Case Report With Positive Maternal and Neonatal Outcomes.

Sugisaki K, Sakauchi M.

J Med Cases. 2023 Apr;14(4):118-123. doi: 10.14740/jmc4083. Epub 2023 Apr 30.

PMID: 37188300 [Free PMC article.](#) Otettu 3.6.23

[A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of **tocilizumab**.](#)

Sugiura F, Kojima T, Oguchi T, Urata S, Yuzawa Y, Sakakibara A, Hayashi H, Nishimoto N, Ishiguro N.

Mod Rheumatol. 2009;19(2):199-203. doi: 10.1007/s10165-008-0132-2. Epub 2008 Nov 6.

PMID:

18987779

[PubMed - indexed for MEDLINE] Otettu 4.5.18

[Related citations](#)

Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to **tocilizumab** treatment.

Sukharomana M, Udomittipong K, Ruangchira-Urai R, Charuvanij S.

Asian Pac J Allergy Immunol. 2019 Dec 14. doi: 10.12932/AP-050819-0616. Online ahead of print.

PMID: 31837211 Otettu 9.1.21

Real-world experience of **tocilizumab** in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients.

Suleman Y, Clark KEN, Cole AR, Ong VH, Denton CP.

Rheumatology (Oxford). 2021 Aug 2;60(8):3945-3946. doi: 10.1093/rheumatology/keab273.

PMID: 33734322 Otettu 6.8.21

New and future perspectives in Behçet's syndrome.

Sulu B, Hatemi G.

Arch Rheumatol. 2024 Dec 18;39(4):511-521. doi: 10.46497/ArchRheumatol.2024.11049. eCollection 2024 Dec.

PMID: 40060132 **Free PMC article.** Review. Otettu 30.3.25

[Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with **tocilizumab**.](#)

Sumida K, Ubara Y, Hoshino J, Suwabe T, Hiramatsu R, Hasegawa E, Hayami N, Yamanouchi M, Sawa N, Takemoto F, Takaichi K.

Clin Rheumatol. 2010 Oct;29(10):1191-4. doi: 10.1007/s10067-010-1418-2. Epub 2010 Mar 12.

PMID:

20225049

[PubMed - indexed for MEDLINE] Otettu 4.5.18

[Related citations](#)

[Successful treatment with humanised anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis.](#)

Sumida K, Ubara Y, Takemoto F, Takaichi K.

Clin Exp Rheumatol. 2011 Jan-Feb;29(1 Suppl 64):S133. Epub 2011 May 11. No abstract available.

PMID:

21385558

[PubMed - indexed for MEDLINE] Otettu 5.4.18

[Related citations](#)

[Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody.](#)

Sumida K, Ubara Y, Suwabe T, Hayami N, Hiramatsu R, Hasegawa E, Yamanouchi M, Hoshino J, Sawa N, Takemoto F, Takaichi K, Ohashi K.

Rheumatology (Oxford). 2011 Oct;50(10):1928-30. doi: 10.1093/rheumatology/ker222. Epub 2011 Jun 29. No abstract available.

PMID:

21719417

[PubMed - indexed for MEDLINE] [Kokotekstinä](#) OK

[Free Article](#)

[Related citations](#)

Select item 21710490805.

[Polymyalgia rheumatica and giant cell arteritis: diagnosis and management.](#)

Sun MM, Pope JE.

Curr Opin Rheumatol. 2024 Oct 15. doi: 10.1097/BOR.0000000000001059. Online ahead of print.

PMID: 39400109 Otta M

[Usefulness of **tocilizumab** for treating rheumatoid arthritis with myelodysplastic syndrome: A case report and literature review.](#)

Sun C, Luo Y, Tong H, Xu G, Lin J.

Medicine (Baltimore). 2018 Jun;97(25):e11179. doi: 10.1097/MD.00000000000011179.

PMID:

Otettu 22.9.18

[Free PMC Article](#)

[Similar articles](#)

Comparison of the efficacy and safety of **tocilizumab**, sarilumab, and sirukumab in comparison with adalimumab as monotherapy in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.

Sung YK, Lee YH.

Int J Clin Pharmacol Ther. 2021 Jul 20. doi: 10.5414/CP204017. Online ahead of print.

PMID: 34281633 Otta M

[Successful maintenance therapy with **tocilizumab** for severe acute liver failure associated with adult-onset still's disease.](#)

Suzuki K, Akiyama M, Nakadai Y, Usui S, Kaneko Y.

Immunol Med. 2024 Aug 5:1-5. doi: 10.1080/25785826.2024.2388346. Online ahead of print.

PMID: 39101771 **Free article.** Otettu 26.11.24

[Anti-inflammatory mechanism of **tocilizumab**, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule.](#)

Suzuki M, Hashizume M, Yoshida H, Mihara M.

Rheumatol Int. 2010 Jan;30(3):309-15. doi: 10.1007/s00296-009-0953-0. Epub 2009 May 23.

PMID:

19466425

[PubMed - indexed for MEDLINE] Otettu 4.5.18

[Related citations](#)

[Optimal time of starting **tocilizumab** in acute phase of adult-onset Still's disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature.](#)

Suzuki S, Kataoka Y, Taniguchi Y, Ikeda K, Tamura N, Morimoto S.

Clin Rheumatol. 2024 Mar;43(3):1245-1251. doi: 10.1007/s10067-024-06905-8. Epub 2024 Feb 12.

PMID: 38342797 **Free PMC article.** Review. Otettu 7.3.24

[Idiopathic multicentric Castleman disease diagnosed after lower extremity venous thrombosis mimicking immunoglobulin G4-related disease - A case report.](#)

Suzuki E, Matsumoto H, Yoshida S, Saito K, Asano T, Odajima H, Kanno T, Migita K.

Intern Med. 2024 Nov 28. doi: 10.2169/internalmedicine.4150-24. Online ahead of print.

PMID: 39603630 **Free article.** Otettu 14.2.25

[Successful high-dose glucocorticoid therapy for anti-mitochondrial antibody-positive myocarditis arising during **tocilizumab** and low-dose glucocorticoid therapy for rheumatoid arthritis.](#)

Suzuki K, Akiyama M, Saito S, Kaneko Y.

Immunol Med. 2024 Apr 5:1-5. doi: 10.1080/25785826.2024.2336689. Online ahead of print.

PMID: 38578159 Otettu 17.4.24

[Therapeutic efficacy of **tocilizumab** in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.](#)

Suzuki T, Horikoshi M, Sugihara M,, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.

Mod Rheumatol. 2013 Jul;23(4):782-7. doi: 10.1007/s10165-012-0746-2. Epub 2012 Sep 14.

PMID:

22975733

[PubMed - indexed for MEDLINE] Otettu 4.5.18

[Related citations](#)

[Subclinical inflammation with **tocilizumab** treatment of rheumatoid arthritis: MRI evaluation for 2 years.](#)

Suzuki T,, Ogishima H, Umeda N, Kondo Y, Yokosawa M, Miki H, Tsuboi H, Matsumoto I, Sumida T.

Int J Rheum Dis. 2014 Oct 7. doi: 10.1111/1756-185X.12460. [Epub ahead of print] No abstract available.

PMID:

25294091

[PubMed - as supplied by publisher] Otettu 4.5.18

[Related citations](#)

[A Case of Rheumatoid Meningitis Diagnosed with FLAIR Images and Anti-cyclic Citrullinated Peptide Antibodies Levels.](#)

Suzuki T, Akamatsu Y, Oshida S, Sato S.

NMC Case Rep J. 2024 Apr 24;11:119-123. doi: 10.2176/jns-nmc.2023-0289. eCollection 2024.

PMID: 38756142 [Free PMC article.](#) Otettu 16.11.24

[Hepcidin-25 gives an indication of the therapeutic effectiveness of **tocilizumab** in rheumatoid arthritis - Relationship between disease activity of rheumatoid arthritis and anemia.](#)

Suzuki S, Nakano S, Ando S, Matsudaira R, Kanai Y, Yamanaka K, Takasaki Y.

Rev Bras Reumatol Engl Ed. 2017 Nov - Dec;57(6):637-640. doi: 10.1016/j.rbre.2016.09.004. Epub 2016 Oct 18. English, Portuguese. No abstract available.

PMID:

29173704 Otettu 5.4.18

Free Article

[Similar articles](#)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, **tocilizumab**, or abatacept in osteoporosis with rheumatoid arthritis.

Suzuki T, Nakamura Y, Kato H.

Ther Clin Risk Manag. 2018 Mar 1;14:453-459. doi: 10.2147/TCRM.S156350. eCollection 2018.

PMID:

29535527 Otettu 5.4.18

Free PMC Article

[Similar articles](#)

Rapid visual recovery following intravenous **tocilizumab** in glucocorticoid resistant refractory giant cell arteritis.

Svasti-Salee CR, Mollan SP, Morgan AW, Quick V.

BMJ Case Rep. 2019 Oct 5;12(10):e229236. doi: 10.1136/bcr-2019-229236.

PMID: 31586951 Otettu 9.1.21

[Clinical Response to **Tocilizumab** in Severe Thyroid Eye Disease.](#)

Sy A, Eliasieh K, Silkiss RZ.

Ophthal Plast Reconstr Surg. 2017 May/Jun;33(3):e55-e57. doi: 10.1097/IOP.0000000000000730.

PMID: Otettu 4.5.18

27281483

[Similar articles](#)

[Successful use of **tocilizumab** in a patient with rheumatoid arthritis following severe pancytopenia during etanercept therapy.](#)

Szalay B, Acs L, Vásárhelyi B, Kovács L, Balog A.

J Clin Rheumatol. 2011 Oct;17(7):377-9. doi: 10.1097/RHU.0b013e318231fd99.

PMID:

21946465

[PubMed - indexed for MEDLINE] Otettu 29.6.15

[Related citations](#)

[Further clinical data on the more rapid achievement of remission without the use of steroids with **tocilizumab** compared to methotrexate in giant-cell arteritis.](#)

Szarpak L, Cander B, Pruc M.

Intern Emerg Med. 2024 Nov 4. doi: 10.1007/s11739-024-03769-3. Online ahead of print.

PMID: 39495354 No abstract available. Otta M

[Successful Use of **Tocilizumab** in a Patient with Coexisting Rheumatoid Arthritis and Ulcerative Colitis.](#)

Szeto MC, Yalçın MD, Khan A, Piotrowicz A.

Case Reports Immunol. 2016;2016:7562123. Epub 2016 Oct 12.

PMID:

27818807 Otettu 5.4.18

[**Free PMC Article**](#)

[Similar articles](#)